US.BMY · Bristol Myers Squibb

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.3,
      "details": {
        "atrPct": 3.2561904761904765,
        "turnoverUsdM": 955.418499,
        "liquidityPoints": 0.6,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.BMY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 58.8972,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 1,
        "rsi_score": 2,
        "macd_score": 2.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 6.5,
      "take_profit_price": 67.6122,
      "target_multiplier": 1.9,
      "technical_strength": 1.78,
      "take_profit_percent": 7.3
    },
    "positionPoints": 1.3,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.512380952380953,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 78.6,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 61.6,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 17
  },
  "market": {
    "ma20": 60.4945,
    "ma50": 63.2616,
    "close": 63,
    "prevClose": 61.12,
    "avgVolume20": 13417984,
    "volumeRatio": 1.13,
    "changePercent": 3.08
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 17,
    "details": {
      "ret_5d": 0.04011887072808329,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 17,
      "vcp_bonus": 2,
      "vol_ratio": 1.1313381539909928,
      "ret_points": 8,
      "vol_points": 2,
      "range_ratio": 1.4652070094700038,
      "volat_points": 2,
      "day_range_pct": 0.04047617460317471,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 78.6,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 80,
        "contribution": 4
      },
      {
        "raw": 11.6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 58,
        "contribution": 11.6
      },
      {
        "raw": 9.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 61.33,
        "contribution": 9.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.5,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 65,
        "contribution": 6.5
      },
      {
        "raw": 22.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 74.33,
        "contribution": 22.3
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 61.6,
    "details": [
      "基本面分析總分: 4/5分",
      "資金流分析總分: 11.6/20分",
      "市場環境分析總分: 9.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.5/10分",
      "技術信號分析總分: 22.3/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4,
      "資金流": 11.6,
      "市場環境": 9.2,
      "情緒分析": 6,
      "技術信號": 22.3,
      "風險管理": 6.5
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.4,
          "marginPoints": 0.6,
          "turnoverUsdM": 955.418499,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.5,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 4,
          "vwapPoints": 3.2,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BMY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.68
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 737.24000235,
                "ma50": 726.3655990799999,
                "name": "QQQ",
                "close": 704.46997,
                "points": 0.4
              },
              "spy": {
                "ma20": 770.7194979,
                "ma50": 768.1665962999998,
                "name": "SPY",
                "close": 763.96002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.2561904761904765,
          "atrPoints": 2,
          "cciPoints": 4,
          "vixPoints": 2.4,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 143102621,
                "url": "https://finnhub.io/api/news?id=5320b00cdee7258de1377b563654ee32a266b9e6613096e3d8687f5e7d7cf2c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1792674021,
                "headline": "Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to Decline"
              },
              {
                "id": 143100356,
                "url": "https://finnhub.io/api/news?id=9a3bd0241c281f404f6c63de944f79638437dcf134236dfcbf25f664aaff0c77",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (BMY) is back in focus after a fresh wave of clinical updates, including new oncology data headed to the ESMO 2026 Congress and recent Phase 3 readouts in cancer and pulmonary fibrosis. All this clinical news is landing after a strong run in Bristol-Myers Squibb’s shares this year. The year-to-date share price return of 14.33% and the 1-year total shareholder return of 43.82% indicate momentum that has cooled slightly in recent weeks as traders reassess risk and pipeline...",
                "category": "company",
                "datetime": 1792671194,
                "headline": "Why Bristol-Myers Squibb (BMY) Is Back In The Spotlight"
              },
              {
                "id": 143070007,
                "url": "https://finnhub.io/api/news?id=9776b97d5259c468789e3151b8bb83caac10ccd11f8472847286924cb34501e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers faces mounting generic competition across its legacy portfolio, while Eliquis delivers strong growth and Revlimid shows resilience amid pricing and market pressures.",
                "category": "company",
                "datetime": 1792587600,
                "headline": "Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?"
              },
              {
                "id": 143030308,
                "url": "https://finnhub.io/api/news?id=eb468f02fe7f64290cb01f91406e776154119f4388e30c7bf51ad199b194906a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Positive Oncology Data Meets an Older-Drug Problem Bristol-Myers Squibb Company (NYSE:BMY) reported positive data from its radiopharmaceutical RYZ101 Phase III ACTION-1 trial and additional progress across multiple myeloma in October. These developments broaden potential sources of revenue, but the valuation question is whether new medicines can scale fast enough to replace sales that will face […]",
                "category": "company",
                "datetime": 1792513880,
                "headline": "Bristol Myers (BMY) Has New Cancer Wins. Can They Offset the Patent Cliff?"
              },
              {
                "id": 143011425,
                "url": "https://finnhub.io/api/news?id=f83bcbb6accb0077c656af33982a29b8e416ae1cd341cf2170e2e901c1ffe701",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (NYSE:BMY) plans to present late-breaking oncology data at ESMO 2026, including new results for pumitamig. The company will also share milestone findings for izalontamab brengitecan (iza bren) that focus on next-generation cancer modalities. Updated long-term survival data for the Opdivo plus Yervoy immunotherapy combination are scheduled for disclosure at the same meeting. The ESMO 2026 data on pumitamig, iza bren and Opdivo plus Yervoy sits against a wider backdrop our...",
                "category": "company",
                "datetime": 1792444122,
                "headline": "Bristol Myers Squibb (BMY) Heads To ESMO 2026 With New Oncology Data"
              },
              {
                "id": 143006602,
                "url": "https://finnhub.io/api/news?id=9728a169ca80180d000b11529722c428022eed793a69affde56634cebddd6c83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) are almost opposites in the pharmaceutical market. One is trying to replace revenue from aging blockbusters, while the other is struggling to keep pace with demand for its newest ones. Yahoo Finance’s most recently available valuation statistics show that Bristol Myers trades at 9.36 times […]",
                "category": "company",
                "datetime": 1792416493,
                "headline": "Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?"
              },
              {
                "id": 142920517,
                "url": "https://finnhub.io/api/news?id=701587138ce30b9430285db4e2baf5be3d87d6d37f42d2393053bca0c14634c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Earlier this week, Bristol Myers Squibb reported positive Phase 3 results for three key programs: RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, admilparant in idiopathic pulmonary fibrosis where only the lower dose met the primary endpoint, and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. Together, these late-stage readouts highlight both the promise and complexity of Bristol Myers Squibb’s next generation portfolio, with new oncology,...",
                "category": "company",
                "datetime": 1792080859,
                "headline": "How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb (BMY) Investors"
              },
              {
                "id": 142882954,
                "url": "https://finnhub.io/api/news?id=9ea93f08c1d2e81ed3c5858c4b3750a9ad571c2db460a201e33883ba24c65e6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1791979204,
                "headline": "Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It"
              }
            ],
            "raw_source": [
              {
                "id": 143104164,
                "url": "https://finnhub.io/api/news?id=ea32a4ec54dc87d8212ecc8cdc5a4e2b36a8e96653548a45a9892cfc01a7fb0e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.",
                "category": "company",
                "datetime": 1792705502,
                "headline": "Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue"
              },
              {
                "id": 143102621,
                "url": "https://finnhub.io/api/news?id=5320b00cdee7258de1377b563654ee32a266b9e6613096e3d8687f5e7d7cf2c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1792674021,
                "headline": "Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to Decline"
              },
              {
                "id": 143100355,
                "url": "https://finnhub.io/api/news?id=8c9f7172c6060025d83f172c3928b7d7d2a65da8f0edac98cfddd36d3845a702",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BOSTON, October 22, 2026--IHI, in partnership with Bristol Myers Squibb (BMS), is launching a new Cancer Collective Action Collaborative.",
                "category": "company",
                "datetime": 1792673700,
                "headline": "IHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical Trials"
              },
              {
                "id": 143100048,
                "url": "https://finnhub.io/api/news?id=2664af14cc6088897231f3cbc67e958e4f4b61005f9bf35b5bd4f94ad44457a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792672351,
                "headline": "Was There Any Sign Merck Stock Would Run?"
              },
              {
                "id": 143100356,
                "url": "https://finnhub.io/api/news?id=9a3bd0241c281f404f6c63de944f79638437dcf134236dfcbf25f664aaff0c77",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (BMY) is back in focus after a fresh wave of clinical updates, including new oncology data headed to the ESMO 2026 Congress and recent Phase 3 readouts in cancer and pulmonary fibrosis. All this clinical news is landing after a strong run in Bristol-Myers Squibb’s shares this year. The year-to-date share price return of 14.33% and the 1-year total shareholder return of 43.82% indicate momentum that has cooled slightly in recent weeks as traders reassess risk and pipeline...",
                "category": "company",
                "datetime": 1792671194,
                "headline": "Why Bristol-Myers Squibb (BMY) Is Back In The Spotlight"
              },
              {
                "id": 143098738,
                "url": "https://finnhub.io/api/news?id=fc60a4943cae745dbafe0392b803c12872eef67a70b0dafa20ab3177db7869b0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors.",
                "category": "company",
                "datetime": 1792668601,
                "headline": "Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility"
              },
              {
                "id": 143098540,
                "url": "https://finnhub.io/api/news?id=37f1b7d370239fd8902383f42b552a182ac95ed7ac2122dc3e2848fd6663674d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Eli Lilly's revenue nearly doubled over two years while Bristol Myers Squibb remained relatively flat, widening the gap between these two pharma giants.",
                "category": "company",
                "datetime": 1792667582,
                "headline": "Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?"
              },
              {
                "id": 143071297,
                "url": "https://finnhub.io/api/news?id=52eab578ffc19c9e3ca9e4df5c44da8f98dac47174e2bd92e488e7e4291514cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792617521,
                "headline": "Are You Overpaying For Regeneron Stock Versus Its Rivals?"
              },
              {
                "id": 143071288,
                "url": "https://finnhub.io/api/news?id=60fab21e4459df56884c06727fb45337dcfb39de578b8bb76a818cb0b9a2c61f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792614371,
                "headline": "Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock?"
              },
              {
                "id": 143070600,
                "url": "https://finnhub.io/api/news?id=41f5226f34db5af377548800478d88791c42319afe872a8b5c18c7788b798c1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "For questions about this article or underlying research, email help@trefis.com.",
                "category": "company",
                "datetime": 1792602406,
                "headline": "What Changed In Amgen's Story?"
              },
              {
                "id": 143067399,
                "url": "https://finnhub.io/api/news?id=41bdb83ce743416c2631fea3df110c559d75437fde7b419026dbcc70aa267750",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth.",
                "category": "company",
                "datetime": 1792588802,
                "headline": "AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?"
              },
              {
                "id": 143070007,
                "url": "https://finnhub.io/api/news?id=9776b97d5259c468789e3151b8bb83caac10ccd11f8472847286924cb34501e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers faces mounting generic competition across its legacy portfolio, while Eliquis delivers strong growth and Revlimid shows resilience amid pricing and market pressures.",
                "category": "company",
                "datetime": 1792587600,
                "headline": "Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?"
              },
              {
                "id": 143062081,
                "url": "https://finnhub.io/api/news?id=7e1de78f5891215345dfd6d2e5515ee4c53718422c4da052c229550a4da162b6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1355632593/image_1355632593.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb yields about 4.3% and trades at 9.1x forward EV/EBIT. Read why BMY stock offers an attractive risk/reward profile.",
                "category": "company",
                "datetime": 1792568710,
                "headline": "Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings"
              },
              {
                "id": 143038856,
                "url": "https://finnhub.io/api/news?id=ec360a4c13d51252fc8575917923e9f0301ecea05f1edc0f73085e8b26ff8f30",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Shares of Merck (MRK) returned 76.2% over the past year, compared with 17.4% for the S&P 500. U.S. growth for the company's cancer drug Keytruda is set to slow. Management said on the August 4 call that U.S. Keytruda growth will moderate as the drug reaches peak penetration across several key indications. Barron's also reported on October 7 that a Dutch court barred Merck from selling subcutaneous Keytruda in eight European markets. So how much of what Merck sells is Keytruda.",
                "category": "company",
                "datetime": 1792549234,
                "headline": "What Happens To Merck Stock If Keytruda Sales Stop Growing?"
              },
              {
                "id": 143033085,
                "url": "https://finnhub.io/api/news?id=368b52ae880d338df7083cf25002b08ab35a8b7af679d3bdc20ca460ccb310e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.",
                "category": "company",
                "datetime": 1792533902,
                "headline": "Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 143030218,
                "url": "https://finnhub.io/api/news?id=e747848b56e46bf9d01a9ff03a13dec6283182b4d2d7bed43caec00c1f2ac2c1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Moderna stock is surging ahead of a closely watched cancer data readout in Madrid, and the stakes could not be higher for a company with nearly $800 million in quarterly losses and no approved cancer product yet.",
                "category": "company",
                "datetime": 1792518806,
                "headline": "Moderna Jumps 7% While Melanoma Vaccine Data Looms; Bristol Myers Squibb Rises 5%, Pfizer Advances 2%"
              },
              {
                "id": 143031680,
                "url": "https://finnhub.io/api/news?id=e11728fc8f5fa19627c71da56097d365124708caa38ac808ec39585063e67696",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "S&P 500 top movers for today's US session: Equifax led gainers at 11.46%, while General Motors led losers at -7.72%, ranked by percentage change.",
                "category": "company",
                "datetime": 1792514161,
                "headline": "S&P 500 Top Movers: Gainers and Losers From Today's US Session"
              },
              {
                "id": 143030308,
                "url": "https://finnhub.io/api/news?id=eb468f02fe7f64290cb01f91406e776154119f4388e30c7bf51ad199b194906a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Positive Oncology Data Meets an Older-Drug Problem Bristol-Myers Squibb Company (NYSE:BMY) reported positive data from its radiopharmaceutical RYZ101 Phase III ACTION-1 trial and additional progress across multiple myeloma in October. These developments broaden potential sources of revenue, but the valuation question is whether new medicines can scale fast enough to replace sales that will face […]",
                "category": "company",
                "datetime": 1792513880,
                "headline": "Bristol Myers (BMY) Has New Cancer Wins. Can They Offset the Patent Cliff?"
              },
              {
                "id": 143030309,
                "url": "https://finnhub.io/api/news?id=fdd9074677ed78006a9d69e256cc0a55f818b266fbf26d101ab83665e4d12ded",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRTA's pharma partnerships offer $3 billion in potential milestone payments plus royalties, but clinical risks and partner control remain key challenges.",
                "category": "company",
                "datetime": 1792510440,
                "headline": "Prothena's Partnership Strategy: Growth Driver or Limitation?"
              },
              {
                "id": 143022202,
                "url": "https://finnhub.io/api/news?id=d76f0331219c48ef73ff897500799a784c9ecb0a902e8aa7cd922de69e742438",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Consider this pharma company's turnaround, not its dividend, its main appeal.",
                "category": "company",
                "datetime": 1792496160,
                "headline": "Have $1,000 to Invest? This Dirt Cheap Pharma Stock Pays You 4.2% to Wait."
              },
              {
                "id": 143021780,
                "url": "https://finnhub.io/api/news?id=88556d7488cd76ab822462dc8b33d441cdc777e7f09396c106d982b327afb2ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.",
                "category": "company",
                "datetime": 1792489790,
                "headline": "3 Unpopular Stocks We Keep Off Our Radar"
              },
              {
                "id": 143020608,
                "url": "https://finnhub.io/api/news?id=5cc767b9143d7093cf8d07efb52939d79cc2dd4f555b5fa8a896fb2d81c14981",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193136073/image_2193136073.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "RIG portfolio review ranks 15 undervalued vs. 15 overvalued dividend stocks using 52-week highs/lows. Check out the list here.",
                "category": "company",
                "datetime": 1792458299,
                "headline": "15 Undervalued Stocks: Yield Up To 7.8% And 15 Overvalued Not To Pursue Now"
              },
              {
                "id": 143011368,
                "url": "https://finnhub.io/api/news?id=73907174e59d10a50f3876040c78a9ce5e2dfc7c2fc5f6c594d7fb6a75bb57f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Key TakeawaysBristol Myers Squibb yields 4. 3% and Merck yields 2.",
                "category": "company",
                "datetime": 1792445509,
                "headline": "Better Dividend Stock: Merck vs. Bristol Myers Squibb"
              },
              {
                "id": 143011424,
                "url": "https://finnhub.io/api/news?id=b6d3477caef86eb97f74d8e69b68a7968e7e2e7818298f50207f2cce9f70dda9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Key TakeawaysBristol Myers Squibb yields 4. 3% and CVS Health yields 3.",
                "category": "company",
                "datetime": 1792444321,
                "headline": "Better Dividend Stock for Retirees: Bristol Myers Squibb vs. CVS Health"
              },
              {
                "id": 143011425,
                "url": "https://finnhub.io/api/news?id=f83bcbb6accb0077c656af33982a29b8e416ae1cd341cf2170e2e901c1ffe701",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (NYSE:BMY) plans to present late-breaking oncology data at ESMO 2026, including new results for pumitamig. The company will also share milestone findings for izalontamab brengitecan (iza bren) that focus on next-generation cancer modalities. Updated long-term survival data for the Opdivo plus Yervoy immunotherapy combination are scheduled for disclosure at the same meeting. The ESMO 2026 data on pumitamig, iza bren and Opdivo plus Yervoy sits against a wider backdrop our...",
                "category": "company",
                "datetime": 1792444122,
                "headline": "Bristol Myers Squibb (BMY) Heads To ESMO 2026 With New Oncology Data"
              },
              {
                "id": 143009574,
                "url": "https://finnhub.io/api/news?id=8070bf91d38ecf0cb55fe6c532381fe54aad64d0db7dcf4b2a2b80d46cc14f93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Regeneron Pharmaceuticals (REGN) stock returned 37.9% in the year to October 16, 2026. This easily outpaced the 16.2% gain for the S&P 500 and left investors looking at a higher price. The underlying business has grown faster lately, yet its operating margin has slipped in each of the past three years. If you buy or hold the shares today, what could three more years of owning them make you.",
                "category": "company",
                "datetime": 1792430174,
                "headline": "How Much Upside Is Left In Regeneron Stock?"
              },
              {
                "id": 143008509,
                "url": "https://finnhub.io/api/news?id=50d1bc3a8e7cdf3b0ac1a17a125d300d6a61758bbaea06444f06dc022823753d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Investors holding Gilead Sciences (GILD) likely bought into a steady profit engine. The company relies on HIV drugs, led by Biktarvy, to earn money year after year and fund a reliable dividend. Gilead spent the first half of 2026 acquiring other businesses, including Arcellx and Tubulis, before reporting its fiscal second quarter on August 4, 2026. What did those deals do to the profit you were counting on.",
                "category": "company",
                "datetime": 1792424621,
                "headline": "What Has Changed About Owning Gilead Stock?"
              },
              {
                "id": 143008550,
                "url": "https://finnhub.io/api/news?id=d6507f450720b95afb3fdabb41d83382773fd3f19fbe3a66ff90817f8f1432c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash generation. The math behind that payout is more uncomfortable than the headline numbers suggest.",
                "category": "company",
                "datetime": 1792422945,
                "headline": "Pfizer’s Dividend Freeze Raises a Bigger Question About Its Cash Flow"
              },
              {
                "id": 143006662,
                "url": "https://finnhub.io/api/news?id=4018028322ba62a71c0bd20e61d8ff986a7942c1337ff3d1ede4676443c39533",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie Inc. (NYSE:ABBV) and Bristol-Myers Squibb Company (NYSE:BMY) are navigating a familiar pharmaceutical challenge, which revolves around replacing revenue from established medicines with newer products. Despite that broad similarity, investors are valuing their progress very differently. According to Yahoo Finance’s valuation data, AbbVie trades at 16.39 times forward earnings, compared with just 9.36 times for […]",
                "category": "company",
                "datetime": 1792417416,
                "headline": "AbbVie vs. Bristol Myers: Is AbbVie’s Valuation Premium Worth Paying?"
              },
              {
                "id": 143006809,
                "url": "https://finnhub.io/api/news?id=d0de61016f78232a9de4e16d7a1ce2dabc48550be4e5de1cf8fdd23003ed65fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb Company (NYSE:BMY) looks cheaper than Pfizer Inc. (NYSE:PFE) on earnings, even though its latest revenue growth was stronger. That sounds like an easy valuation story until the profit figures enter the picture. Bristol Myers reported a 40% rise in second-quarter adjusted earnings per share, while Pfizer’s adjusted earnings were virtually unchanged. But those […]",
                "category": "company",
                "datetime": 1792417157,
                "headline": "Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch"
              },
              {
                "id": 143006602,
                "url": "https://finnhub.io/api/news?id=9728a169ca80180d000b11529722c428022eed793a69affde56634cebddd6c83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) are almost opposites in the pharmaceutical market. One is trying to replace revenue from aging blockbusters, while the other is struggling to keep pace with demand for its newest ones. Yahoo Finance’s most recently available valuation statistics show that Bristol Myers trades at 9.36 times […]",
                "category": "company",
                "datetime": 1792416493,
                "headline": "Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?"
              },
              {
                "id": 143008554,
                "url": "https://finnhub.io/api/news?id=008230e38a161a74046be81c0613e072673cebd7dc95d506b53860a1629fc0b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer's Q3 results will shed light on its non-oncology portfolio, as demand trends, pricing pressure and vaccine sales shape performance across key therapies.",
                "category": "company",
                "datetime": 1792416300,
                "headline": "Pfizer's Non-Oncology Performance in Q3: Driving Factors to Watch"
              },
              {
                "id": 143006878,
                "url": "https://finnhub.io/api/news?id=77ae91710ec03eec8dbe81de459c684b998e07502fde99aa5a778307157e3b92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.",
                "category": "company",
                "datetime": 1792413600,
                "headline": "Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?"
              },
              {
                "id": 143006877,
                "url": "https://finnhub.io/api/news?id=7701c15443aa8c89021a426f1c87efca7e1421a50305db7608f32c89da01244d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that four abstracts for iza-bren (izalontamab brengitecan), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC), will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27 in Madrid, Spain. Iza-bren is being developed under a license and collaboration agreement by and between SystImmune and Bristol Myers Squibb.",
                "category": "company",
                "datetime": 1792411200,
                "headline": "SystImmune, Inc. to Present New Phase 3 Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated NSCLC, HR+ Breast Cancer, and Phase 2 Data in Head and Neck Cancer at ESMO 2026"
              },
              {
                "id": 143004407,
                "url": "https://finnhub.io/api/news?id=1594e6fe3360be98987fab9972b8c5b3bd05d11955f7ad3b5941dc4ab9b6faa0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., October 19, 2026--Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026",
                "category": "company",
                "datetime": 1792407540,
                "headline": "Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026"
              },
              {
                "id": 143007392,
                "url": "https://finnhub.io/api/news?id=aa60e190840f2a6f4f879452c2bb966c6926bf424c3564aea0543a681b956df5",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in patients with metastatic",
                "category": "company",
                "datetime": 1792392509,
                "headline": "BioNTech To Present New Clinical Data From Its Late-Stage Oncology Pipeline With 16 Abstracts At European Society For Medical Oncology, October 23–27; Key Oral Presentations Will Focus On Clinical Data For Pumitamig Plus Docetaxel In Second-Line Metastatic Non-Small Cell Lung Cancer"
              },
              {
                "id": 142960211,
                "url": "https://finnhub.io/api/news?id=3cd6b334dacd22b1da54c95de7946c5985810e696ccdc4478ddbe6dac4398fb7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding shares for income, consider what the pending Apogee deal and lingering debt load could mean for the payout's future.",
                "category": "company",
                "datetime": 1792238420,
                "headline": "AbbVie’s Dividend Keeps Climbing. Is It Still a Buy for Income Investors?"
              },
              {
                "id": 142956254,
                "url": "https://finnhub.io/api/news?id=0936d03373bb17e263e876ceb2e2b2190733d790f2fa4fc4d26706b91436d608",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.",
                "category": "company",
                "datetime": 1792199402,
                "headline": "Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142955409,
                "url": "https://finnhub.io/api/news?id=ddb56e3c9661675f49062aebfa86d5d29be9a5e9841df1481875ad51a4717ce5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock has gained 15.2%, outpacing the 1.9% return of the S&P 500. A higher forecast or a climbing share price means little in isolation. When the corporate numbers and the technical chart align, however, the combination warrants closer scrutiny. So how far did management raise its forecast, and why.",
                "category": "company",
                "datetime": 1792198389,
                "headline": "When Amgen's Forecast And Chart Say The Same Thing, Pay Attention"
              },
              {
                "id": 142954216,
                "url": "https://finnhub.io/api/news?id=4ceb14cf168e6a03b7c306392042043ca662a3e864ad75e2c2967d3eb042758f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Gilead Sciences (GILD) built its foundation on HIV treatment. Biktarvy alone accounted for $14.3 billion of the company's $29.4 billion in fiscal 2025 revenue. Yet another segment of the HIV business is growing at a much faster pace, and it targets people who do not currently carry the virus. Gilead expects a regulatory decision regarding a new option in this category in early 2027. So what is that business, and how much is it selling today.",
                "category": "company",
                "datetime": 1792197478,
                "headline": "Gilead’s HIV Prevention Business Just Topped $1 Billion A Quarter. What Comes Next?"
              },
              {
                "id": 142953213,
                "url": "https://finnhub.io/api/news?id=e0d5644bdb1a894b876cd8a527913e2c730f1125e7d0685ae819033f70376096",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that position with broad exposure to the S&P 500. As the broader market rises and falls each day, the pharmaceutical stock's individual performance blends with the rest of that capital. So when the market drops, does Amgen make your losses bigger.",
                "category": "company",
                "datetime": 1792196033,
                "headline": "Is Amgen Stock Increasing Your Market Risk?"
              },
              {
                "id": 142949141,
                "url": "https://finnhub.io/api/news?id=7f878e1d7b8e6ca6594ebcc4d0bd6c82c52bece760c60ab0ea552e559d275df8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increases on a collision course with the drugs Wall Street is betting everything on.",
                "category": "company",
                "datetime": 1792172719,
                "headline": "Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know"
              },
              {
                "id": 142948096,
                "url": "https://finnhub.io/api/news?id=88c2f8572ba56df87ae6c61f075f69677bc6f99d8c8792695266c626b2db4658",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Over the last year, Bristol-Myers Squibb Company (NYSE:BMY) has done better than the overall market, with its shares increasing by nearly 40% as a result of new medicines contributing to revenue growth and management having raised its earnings forecast. Nevertheless, the pharmaceutical company is currently trading at just 9.36 times forward earnings, indicating that investors […]",
                "category": "company",
                "datetime": 1792164527,
                "headline": "Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?"
              },
              {
                "id": 142944345,
                "url": "https://finnhub.io/api/news?id=0ffe996e3f53c5aa13ace5dbb9b5c918d63302d8129a0d8f02f05d2c02a69908",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb recently reported positive Phase 3 topline data across three late stage programs, including RYZ101 in GEP NETs, admilparant in idiopathic pulmonary fibrosis and ZENBEXUS in relapsed or refractory multiple myeloma. This cluster of past trial readouts highlights how Bristol Myers Squibb’s late stage pipeline breadth could matter for replacing revenue at risk from aging therapies. We will look at how Bristol Myers Squibb’s investment narrative evolves as positive...",
                "category": "company",
                "datetime": 1792149290,
                "headline": "How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors"
              },
              {
                "id": 142940521,
                "url": "https://finnhub.io/api/news?id=e3e7f2be453bd973524c30714cc4668a22768d7deb2ec2c4b975fb38543b4c09",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Bristol Myers Squibb is executing a visible portfolio transition, with its Growth Portfolio now surpassing Legacy Portfolio. Read more on BMY stock here.",
                "category": "company",
                "datetime": 1792130135,
                "headline": "Bristol Myers Squibb: The New Portfolio Is Starting To Carry More Of The Business"
              },
              {
                "id": 142922269,
                "url": "https://finnhub.io/api/news?id=c7865f7724923f82ec5f2ffee87e7389c60a2dc5ec98a0c9ffd0eb37e2d969ae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand exactly what they hold, and the drugmaker's priorities have changed. During the fiscal Q4 2024 call in February 2025, executives noted that conditions for the GARDASIL vaccine in China remained challenging. By the August 4, 2026 call, management emphasized something else. So what does management talk up now.",
                "category": "company",
                "datetime": 1792093589,
                "headline": "How Has Merck's Story Changed?"
              },
              {
                "id": 142921460,
                "url": "https://finnhub.io/api/news?id=7d2eaf020ea1d1411a948a5847acdce274d5dcca2c046a7cc850c0b529bb1a12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.",
                "category": "company",
                "datetime": 1792084620,
                "headline": "Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?"
              },
              {
                "id": 142920516,
                "url": "https://finnhub.io/api/news?id=b11205f6e133d2d45e5cc8fff9cbf7acc04e641dd42f7d79ec85e1f3245733ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb's (BMY) LPA1 antagonist admilparant can still be viable despite recent mixed re",
                "category": "company",
                "datetime": 1792084268,
                "headline": "Bristol-Myers Squibb's Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says"
              },
              {
                "id": 142920518,
                "url": "https://finnhub.io/api/news?id=160dac88c27166f9bac3e2e571323afa4058b2bdaadfcc9fd76eef02c1b202ec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Six popular dividend stocks sitting in a taxable account quietly hand a portion of every payout to the IRS, and the gap between what you earn and what you keep widens sharply depending on which bracket you occupy and which account holds the shares.",
                "category": "company",
                "datetime": 1792080941,
                "headline": "A $600,000 Dividend Portfolio Has a $52,900 Tax Problem. Here’s the Roth Solution"
              },
              {
                "id": 142920517,
                "url": "https://finnhub.io/api/news?id=701587138ce30b9430285db4e2baf5be3d87d6d37f42d2393053bca0c14634c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Earlier this week, Bristol Myers Squibb reported positive Phase 3 results for three key programs: RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, admilparant in idiopathic pulmonary fibrosis where only the lower dose met the primary endpoint, and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. Together, these late-stage readouts highlight both the promise and complexity of Bristol Myers Squibb’s next generation portfolio, with new oncology,...",
                "category": "company",
                "datetime": 1792080859,
                "headline": "How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb (BMY) Investors"
              },
              {
                "id": 142918338,
                "url": "https://finnhub.io/api/news?id=e19a0fb272e46fb19137d8128338fccfc0f3a747983c2cab0d144179c2de9d1a",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Thursday to uncover the stocks that are gapping in the S&P500 index.",
                "category": "company",
                "datetime": 1792074903,
                "headline": "These S&P500 stocks are gapping in today's session"
              },
              {
                "id": 142919414,
                "url": "https://finnhub.io/api/news?id=158df650bf30e4910ada1181e4a1cdfb4a1dccf0a0968cd6512cdc0c83cefa23",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Recently published Neuroendocrine Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, neuroendocrine prostate cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].",
                "category": "company",
                "datetime": 1792074660,
                "headline": "Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs, BsAbs, CAR-Ts, Aurora Kinase Inhibitors, and EZH2 Inhibitors | DelveInsight"
              },
              {
                "id": 142919904,
                "url": "https://finnhub.io/api/news?id=10e4343537faceb2924284039eb4ed431ab6462c2e4f47042d7cba8b0e03e2a0",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2186944301/image_2186944301.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Alto Neuroscience, Inc. pivots to ALTO-207 for treatment-resistant depression; learn risks, catalysts, dilution, and outlook. Click for this ANRO stock update.",
                "category": "company",
                "datetime": 1792069651,
                "headline": "Alto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To Hold"
              },
              {
                "id": 142915179,
                "url": "https://finnhub.io/api/news?id=dd1a9ab1ccd72a6dd56ee5201dc4f9dafcd0381386b2fe7aaeba9884768c76c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "New types of bispecifics, ADCs and CAR-Ts are still proving themselves in the clinic — pharma’s betting billions anyway.",
                "category": "company",
                "datetime": 1792068922,
                "headline": "Hype vs. reality: What pharma’s hottest R&D bets have actually proved"
              },
              {
                "id": 142889244,
                "url": "https://finnhub.io/api/news?id=434733031d20fe4cdc19bc79cf48d12b65f1d04ad018b78d4055f1173b8c98bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying down a balance owed to its partner Sanofi. This obligation reduced the revenue Regeneron reported from the partnership. So what does Regeneron gain now that the balance is paid off.",
                "category": "company",
                "datetime": 1792014348,
                "headline": "What Could Send Regeneron Stock Higher?"
              },
              {
                "id": 142887222,
                "url": "https://finnhub.io/api/news?id=0b7c292179b56ca652306005b9567d0a0523eab678139849606472987ea2e20f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1792004701,
                "headline": "Top S&P500 movers in Wednesday's session"
              },
              {
                "id": 142886500,
                "url": "https://finnhub.io/api/news?id=a6a4f6f24c866e68c6cde594f797d5868f29abd7851bb0d3528f7a171b7a2d54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Four companies kept raising their dividends even as the pandemic hammered their sectors in 2020, and they are still raising today. The question is whether their yields and valuations make them worth buying right now.",
                "category": "company",
                "datetime": 1791998106,
                "headline": "These 4 Dividend Stocks Passed the 2020 Stress Test. Are They Buys in Now October?"
              },
              {
                "id": 142885916,
                "url": "https://finnhub.io/api/news?id=b622cb959cbffaf6a3f606c989db14bb104d90fd68454f6db70586c3daa7cf5d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.",
                "category": "company",
                "datetime": 1791995703,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 142885198,
                "url": "https://finnhub.io/api/news?id=8fe4192fca1e3129d408489e0653fb7f18bb59e735badf4ccd9ef4299f943ff5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "MRK's Keytruda sales growth, earlier-stage launches and expanded indications could boost Q3 results, but biosimilar competition looms in 2028-2029.",
                "category": "company",
                "datetime": 1791985560,
                "headline": "Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?"
              },
              {
                "id": 142882954,
                "url": "https://finnhub.io/api/news?id=9ea93f08c1d2e81ed3c5858c4b3750a9ad571c2db460a201e33883ba24c65e6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
                "category": "company",
                "datetime": 1791979204,
                "headline": "Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 142881810,
                "url": "https://finnhub.io/api/news?id=438120ffde9775af72c243c75dffe1796b2b14de58c6775d05928ecea5d80129",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Today, CIBC announced its intention to list 11 new U.S. Canadian Depositary Receipts (\"CDRs\") on the TSX, with trading expected to begin on October 20, 2026. With these additions, CIBC will now offer 144 CDRs across six countries.",
                "category": "company",
                "datetime": 1791979200,
                "headline": "CIBC to launch additional U.S. Canadian Depositary Receipts"
              },
              {
                "id": 142881695,
                "url": "https://finnhub.io/api/news?id=7fea1d49ce468ac5cda1986cdec52c42bb30275066096747e2bcadca75f062b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway. The five names on this list have already replaced their fading blockbusters with something bigger, and the math behind their payouts tells the story.",
                "category": "company",
                "datetime": 1791976502,
                "headline": "Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying"
              },
              {
                "id": 142856069,
                "url": "https://finnhub.io/api/news?id=19ddbf443d05e538002ed8fb8a4b92ac9ed26efb14a4416a1787066e2d586672",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. The company ranks second within this group for both sales growth and operating margin. Its valuation tells a different story. Leaving out Merck and Pfizer, which each reported a loss in at least one of their last four quarters, Amgen has the third highest P/E of the four companies that can be compared. So how far apart are what Amgen delivers and what",
                "category": "company",
                "datetime": 1791935331,
                "headline": "Is Amgen Stock Worth More Than Its Competitors?"
              },
              {
                "id": 142854405,
                "url": "https://finnhub.io/api/news?id=f5f9405e2da0760b133cb05dfa696dcf98dcf4c6f810b084de1333fbe65a9b91",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate.",
                "category": "company",
                "datetime": 1791925922,
                "headline": "Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142854423,
                "url": "https://finnhub.io/api/news?id=5bc081dc70d815ffa88823067c5acd0248f42961683e09e9d61876123ee214f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer (PFE) and Bristol-Myers Squibb (BMY) are bought for the same underlying reason: the search for new drugs to replace older ones losing market exclusivity. Both drugmakers point to 2028 as the year that matters. Pfizer is acquiring drugs and cutting costs to bridge the gap, while Bristol Myers still relies on Eliquis, an older drug that continues to grow. So what did each company tell investors at its latest report about how that replacement is going.",
                "category": "company",
                "datetime": 1791921571,
                "headline": "What Does Bristol-Myers Squibb Offer That Pfizer Does Not?"
              },
              {
                "id": 142852570,
                "url": "https://finnhub.io/api/news?id=585ec92d555024f138a73d02be2ce5350e1eec52b7ca1641fee4a668d0352192",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.",
                "category": "company",
                "datetime": 1791909600,
                "headline": "BMY Reports Mixed Phase III Trial Results, Stock Down"
              },
              {
                "id": 142852569,
                "url": "https://finnhub.io/api/news?id=3af08ef327b1a3960efcd04456822a3362fc7e4c6f832a1ff86a9034641a7642",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Treatment for a serious lung disease failed to meet the company’s primary goal.",
                "category": "company",
                "datetime": 1791905040,
                "headline": "Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans."
              },
              {
                "id": 142851360,
                "url": "https://finnhub.io/api/news?id=e4825afb73f81541d113f625c84f508dbcc80da4537658d1b2bda11a00dcc239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb has delivered a strong 38.1% share price gain over the past year, even as shorter term moves have been weaker. This naturally raises the question of whether that climb is fully supported by the earnings the business is generating today. That 38.1% one year return puts more weight on the question of whether the current valuation is still in line with what Bristol-Myers Squibb actually earns. Fresh positive late stage trial results across cancer, cardiology and respiratory...",
                "category": "company",
                "datetime": 1791904544,
                "headline": "Bristol Myers Squibb (BMY) Stock Trades At A Discount Following Its 38% Run"
              },
              {
                "id": 142851361,
                "url": "https://finnhub.io/api/news?id=3b9b1b0a2b7d057257aeecd7ba057dc4a7069f53a740f22f20ba3a36878759e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 data for admilparant in idiopathic pulmonary fibrosis and RYZ101 in gastroenteropancreatic neuroendocrine tumors. Admilparant showed significant clinical benefits and a favorable safety profile in idiopathic pulmonary fibrosis, targeting a serious chronic lung disease. RYZ101 improved progression free survival in patients with gastroenteropancreatic neuroendocrine tumors, supporting upcoming regulatory discussions. The Phase 3 wins...",
                "category": "company",
                "datetime": 1791900756,
                "headline": "What Could Bristol Myers Squibb (BMY) Two Phase 3 Wins Change?"
              },
              {
                "id": 142882290,
                "url": "https://finnhub.io/api/news?id=dad524e982dd6c58bdb1fa3180264aef3534e3fa2d3d927ace66c7ffc4b03f05",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1791898511,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 142848882,
                "url": "https://finnhub.io/api/news?id=ef8ac0d1e97e5968da783d85fb17741fdd37294b8a0fae0eb6fcbce12d84f45c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BlackLine’s 2026 Modern Accounting Awards Recognize Booking Holdings, Bristol Myers Squibb, James Hardie, LAZ Parking, Payoneer, and US FoodsLOS ANGELES, Oct. 13, 2026 (GLOBE NEWSWIRE) -- BlackLine, Inc. (Nasdaq: BL) announced the winners of its 2026 Modern Accounting Awards, celebrating six enterprise leaders that are redefining how modern finance and accounting teams work. This year’s honorees achieved large-scale operational breakthroughs by combining unified data architectures with intellige",
                "category": "company",
                "datetime": 1791896400,
                "headline": "BlackLine Honors Global Enterprise Leaders Transforming Financial Operations"
              },
              {
                "id": 142848724,
                "url": "https://finnhub.io/api/news?id=315e5b90b29557409d7909d1fcb72ca492a6c4489ba8c21964d6e25559c354ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "New ranking recognizes 650 U.S. companies for performance in environmental sustainabilityNEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Newsweek, in partnership with Plant-A Insights Group, today announced America’s Greenest Companies 2027, recognizing 650 U.S. companies for their performance in environmental sustainability. Kraft Heinz, T-Mobile, Otis, Hasbro, Citi, Bristol Myers Squibb and Applied Materials are among the companies earning the highest five-star distinction. As sustainability becom",
                "category": "company",
                "datetime": 1791896400,
                "headline": "Kraft Heinz, T-Mobile, Otis, Hasbro and Citi Named Among Newsweek’s America’s Greenest Companies 2027"
              },
              {
                "id": 142848880,
                "url": "https://finnhub.io/api/news?id=b9002e411acf914659357cc029110a7b59cb56aa34dc56fa719830ee03257903",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Originally published on preventcancer.orgThis post has been sponsored by Bristol Myers Squibb as part of its sponsorship of the 2026 Prevent Cancer Gala.",
                "category": "company",
                "datetime": 1791894600,
                "headline": "Advancing Access to Lung Cancer Care Through Artificial Intelligence Innovation"
              },
              {
                "id": 142848664,
                "url": "https://finnhub.io/api/news?id=d6cc5a18341120b4042d9c7782d95ce246363cae42d5930c60a8044f46d2e33f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them.",
                "category": "company",
                "datetime": 1791892852,
                "headline": "Why A Biotech M&A Wave May Hit This Winter"
              },
              {
                "id": 142848709,
                "url": "https://finnhub.io/api/news?id=b0ef2a06f8b01d293983da938d732d1beef04ee585352e83aefb422ae6bb40f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "With Just Two Days Remaining, Qualified Technology Executives Are Encouraged to Register in AdvanceFAIRFIELD, Conn., Oct. 13, 2026 (GLOBE NEWSWIRE) -- With only two days remaining before HMG Strategy's 19th Annual Greenwich C-Level Technology Leadership Summit, more than 125 CIOs, CISOs, CTOs, Chief Digital Officers and senior technology executives from leading organizations across Connecticut, Westchester County, New York City and the Northeast have registered to attend the event on October 15",
                "category": "company",
                "datetime": 1791892800,
                "headline": "More Than 125 Technology Leaders Registered for HMG Strategy's 19th Annual Greenwich C-Level Technology Leadership Summit on October 15"
              },
              {
                "id": 142884862,
                "url": "https://finnhub.io/api/news?id=aeab9fdd4a3fc1e0859e1ef7e59cd24a70f0fdd515f787df0b7af704d351ee67",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Wells Fargo  analyst Mohit Bansal   maintains Bristol-Myers Squibb (NYSE:BMY) with a Equal-Weight and lowers the price target from $65 to $60.",
                "category": "company",
                "datetime": 1791888769,
                "headline": "Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $60"
              },
              {
                "id": 142852568,
                "url": "https://finnhub.io/api/news?id=9ba90c18a0db3bea412086dd81b6742aae56154f1db17f68bfd84325cc52d0ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb is set to announce its third-quarter earnings later this month, and analysts expect the company's bottom line to shrink by a single-digit percentage.",
                "category": "company",
                "datetime": 1791886877,
                "headline": "Bristol-Myers Squibb's Quarterly Earnings Preview: What You Need to Know"
              },
              {
                "id": 142824603,
                "url": "https://finnhub.io/api/news?id=24f3cd5805571d58404aed677349fb75a92c1d17fade64b771ad65f28cc3fbe6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (BMY) reached $57.6 at the closing of the latest trading day, reflecting a -2.58% change compared to its last close.",
                "category": "company",
                "datetime": 1791837903,
                "headline": "Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today"
              },
              {
                "id": 142823670,
                "url": "https://finnhub.io/api/news?id=5fcf98e656cace331f2453ea7672ef37921d4739c8dd76fe6128164881780509",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He",
                "category": "company",
                "datetime": 1791834672,
                "headline": "Sector Update: Healthcare Stocks Rise Late Afternoon"
              },
              {
                "id": 142823765,
                "url": "https://finnhub.io/api/news?id=96e15c0ee8d6d0fc2cd258ecd0f9fd393a386da4fa3e0e25243e30ad9a6c7508",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028.",
                "category": "company",
                "datetime": 1791830760,
                "headline": "Bristol Myers Stock Tumbles on ‘Confounding’ Trial Results"
              },
              {
                "id": 142822840,
                "url": "https://finnhub.io/api/news?id=96f03d013fc64ca1fb56274ee3257447616ec7ea68d92fba536bb4a9556c7a0d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers reported that its late-stage ALOFT-IPF trial of the oral drug admilparant met the primary endpoint at the 60 mg twice-daily dose in patients with Idiopathic Pulmonary Fibrosis.",
                "category": "company",
                "datetime": 1791825605,
                "headline": "BMY Stock Drops As Lower-Dose Lung Drug Succeeds In Trial, Higher Dose Misses"
              },
              {
                "id": 142822841,
                "url": "https://finnhub.io/api/news?id=a2d10f1bdbfcaafe57be154642c494f1c193586c800165fd2e282037fda5af3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP) shares fell 3% to $57.39 after positive results from a late-stage trial of an experimental cancer treatment raised questions about the market’s reaction to the announcement. The US drugmaker reported that its ACTION-1 Phase 3 trial met...",
                "category": "company",
                "datetime": 1791824700,
                "headline": "Bristol Myers falls 3% despite positive cancer drug trial results"
              },
              {
                "id": 142822842,
                "url": "https://finnhub.io/api/news?id=aff29a891d2f18a3ad2ec6a1bd129c42e2d2a66d000b3e361e97e01632f631ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BMS will be speaking with regulatory authorities based on data from the pivotal trial of the IPF drug.",
                "category": "company",
                "datetime": 1791820485,
                "headline": "BMS gains two pivotal trial wins in lung disease and rare cancer"
              },
              {
                "id": 142821742,
                "url": "https://finnhub.io/api/news?id=eecf9aaf535f0ff33ee2f741ad8cd3eb7c384cd5087842b5f9a98bab5474c7f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.",
                "category": "company",
                "datetime": 1791819300,
                "headline": "Bristol Myers dips on ‘confounding’ lung drug results"
              },
              {
                "id": 142821650,
                "url": "https://finnhub.io/api/news?id=5da3845e8880e1b163c09a9039958c5ccb97443572c73a7ab29a55a8ad052c3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers shares surge 35.8% as its Growth Portfolio and pipeline progress fuel momentum, but generic competition and valuation warrant caution.",
                "category": "company",
                "datetime": 1791816480,
                "headline": "BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?"
              },
              {
                "id": 142821743,
                "url": "https://finnhub.io/api/news?id=fd936cb3a6e370b953f414c1f9bd19cabba000401207c3334cfdb1f096dc9d51",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb scored two Phase 3 wins on Monday in lung disease and cancer. The stock fell, however.",
                "category": "company",
                "datetime": 1791816160,
                "headline": "Bristol Myers Reverses Lower Despite Double Phase 3 Win, As A Key Rival Crashes"
              },
              {
                "id": 142821730,
                "url": "https://finnhub.io/api/news?id=dff9a0c97d259797b19fb4e41b1aa26f160d008278d2e20474435162bc6c6088",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb is making a $4.1 billion bet on radiopharmaceutical cancer drugs ahead of a major patent cliff in 2028.",
                "category": "company",
                "datetime": 1791814500,
                "headline": "Bristol Myers Stock Is Rising on a Double Dose of Good News"
              },
              {
                "id": 142820096,
                "url": "https://finnhub.io/api/news?id=b8a00e0650e708c68e13ef8ef9bc61f1eabd5ddb871ac36ed98989cfbcfd4889",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb scored two Phase 3 wins on Monday in lung disease and cancer. The stock rose, while a key rival plummeted.",
                "category": "company",
                "datetime": 1791812036,
                "headline": "Bristol Myers Scores Two Phase 3 Wins, But A Key Rival Plummets On One"
              },
              {
                "id": 142849121,
                "url": "https://finnhub.io/api/news?id=293321bcb15f65e23f43b15ce81a3084b29292761ddd742ced7bb84a1a1f11fe",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/12/Lung-cancer-study.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "BMS trial results trigger a 29% drop in Contineum (CTNM), but analysts highlight long-term potential for PIPE-791 in IPF.",
                "category": "company",
                "datetime": 1791809982,
                "headline": "Why Is Contineum Therapeutics Stock Falling Monday?"
              },
              {
                "id": 142820097,
                "url": "https://finnhub.io/api/news?id=5cf74187f5674558278ec275c85d5852d76f4d453ddd54d5631a4eabe717d9c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Contineum Therapeutics (NASDAQ:CTNM) shares climbed 27% in premarket trading on Monday after Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 clinical trial results for a pulmonary fibrosis treatment targeting the same biological pathway as Contineum’s lead drug candidate. Contineum shares were indicated at $16.",
                "category": "company",
                "datetime": 1791808967,
                "headline": "Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results"
              },
              {
                "id": 142820098,
                "url": "https://finnhub.io/api/news?id=b962cea5c14be645a6848d3e0dfafcd69d2ea7c6f100619f56e5f3d650fbe206",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (NYSE:BMY) shares rose 6. 5% on Monday after the pharmaceutical company announced positive results from two Phase 3 clinical trials evaluating treatments for neuroendocrine tumours and idiopathic pulmonary fibrosis.",
                "category": "company",
                "datetime": 1791808834,
                "headline": "Bristol Myers Squibb Shares Jump 6.5% Following Positive Phase 3 Trial Results for Two Therapies"
              },
              {
                "id": 142819368,
                "url": "https://finnhub.io/api/news?id=07790595272c5552eeb9761d5fde2990c182b228c2dfe7de944815e11443ca2d",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "Get insights into the top gainers and losers in the S&P500 index of Monday's pre-market session.",
                "category": "company",
                "datetime": 1791808501,
                "headline": "Stay updated with the S&P500 stocks that are on the move in today's pre-market session."
              },
              {
                "id": 142820099,
                "url": "https://finnhub.io/api/news?id=0de70e73ff5bf208f738f2ea05759e5274173a7602426d544f5243b7aa567926",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Investing.com -- Contineum Therapeutics (NASDAQ:CTNM) shares reversed course and fell 25% in Monday trading, erasing an initial 27% pre-market surge following Bristol Myers Squibb’s (BMY) announcement that its Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis (IPF) met its primary endpoint.",
                "category": "company",
                "datetime": 1791806116,
                "headline": "Contineum drops 25% on mixed Bristol Myers IPF data; Stifel keeps Buy rating"
              },
              {
                "id": 142819169,
                "url": "https://finnhub.io/api/news?id=72a02883f80ffed0e7dfe9e9fe245bc2b6d032b558a236ea282aecb0b8f227b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Investing.com -- Bristol Myers Squibb (NYSE: BMY) shares surged 6.5% on Monday following the announcement of positive top-line results from two separate Phase 3 clinical trials evaluating targeted therapies for neuroendocrine tumors and idiopathic pulmonary fibrosis. [pro_promotion |",
                "category": "company",
                "datetime": 1791805013,
                "headline": "Bristol Myers Squibb stock surges on dual phase 3 clinical trial successes"
              },
              {
                "id": 142819170,
                "url": "https://finnhub.io/api/news?id=cee10ddcf20697816ec2b96482a4a6365766ca954c28a75418268657516bde20",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., October 12, 2026--BMS Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101",
                "category": "company",
                "datetime": 1791802500,
                "headline": "Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs"
              },
              {
                "id": 142819171,
                "url": "https://finnhub.io/api/news?id=9bae07c5edfb89b59f8e0165f194bdf91ab7a4248324545f7d7b72321a40822c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., October 12, 2026--Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint",
                "category": "company",
                "datetime": 1791802200,
                "headline": "Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint"
              },
              {
                "id": 142821256,
                "url": "https://finnhub.io/api/news?id=1a29b3f23b798ef3d3884f77620c2607b7b6a8dc231e90c08aaab75fed87c022",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/12/Rueil-malmaison--France---August-13--202.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Bristol Myers Squibb stock jumped over 4% after positive Phase 3 results for neuroendocrine tumors and pulmonary fibrosis treatments.",
                "category": "company",
                "datetime": 1791792165,
                "headline": "Why Is Bristol Myers Squibb Stock Gaining Monday?"
              },
              {
                "id": 142816422,
                "url": "https://finnhub.io/api/news?id=b5b664f4eb5c373e04b0a1b7343deb105d7aed92ed763508a0eb9bc000e7ca73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Reinforcing its commitment to putting patients at the centre of everything it does, Bristol Myers Squibb (BMS), a leading global biopharmaceutical company, recently celebrated the 12th edition of its annual Global Patient Week in the Kingdom of Saudi Arabia. As part of this year's activities, BMS joined forces with the Saudi Schizophrenia Association ('Ehtiwaa') to support individuals living with schizophrenia through a practical, hands-on wellness initiative: the 'Small Wins: Everyday Activity",
                "category": "company",
                "datetime": 1791792000,
                "headline": "On the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' Initiative"
              },
              {
                "id": 142821257,
                "url": "https://finnhub.io/api/news?id=050e10d580981c2318f9a5e72e4afb806d1422b74ee851a07477e3b22296d105",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (NYSE:BMY) today announced positive topline results from the planned interim analysis of the ACTION-1 trial (NCT05477576) conducted by RayzeBio, Inc., a Bristol Myers Squibb company. The study met",
                "category": "company",
                "datetime": 1791788592,
                "headline": "Bristol Myers Squibb Announces Topline Results From Unit RayzeBio's Planned Interim Analysis Of ACTION-1 Trial; RYZ101 Study Met Primary Endpoint With Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival By Blinded Independent Central Review, And Safety Results Consistent With Known Safety Profile"
              },
              {
                "id": 142821258,
                "url": "https://finnhub.io/api/news?id=21695ffc3b70620e1106479b6f7f81903286db558b1af0040fa6b70c76f8438e",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "In the trial, admilparant at the 60 mg dose demonstrated a statistically significant benefit in absolute change in forced vital capacity (FVC) from baseline to Week 52 compared with placeboAdmilparant demonstrated a",
                "category": "company",
                "datetime": 1791787912,
                "headline": "Bristol Myers Squibb's Admilparant Meets Phase 3 Primary Endpoint in Idiopathic Pulmonary Fibrosis Trial"
              },
              {
                "id": 142810093,
                "url": "https://finnhub.io/api/news?id=98c661ed0ff45874a7168ff5b1c6dc60fcb3a928f3e7f81d04a689c19ab0abc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The ASH meeting runs Dec. 12-Dec. 15 in New Orleans. Sellas is listed at Booth 138, and more than 275 exhibitors are expected.",
                "category": "company",
                "datetime": 1791768132,
                "headline": "SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH"
              },
              {
                "id": 142797825,
                "url": "https://finnhub.io/api/news?id=d0e4c844dfa87ed4f53dd4d26660626a03de6fc78fae246c12d12553264f870b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.",
                "category": "company",
                "datetime": 1791686100,
                "headline": "How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?"
              },
              {
                "id": 142794266,
                "url": "https://finnhub.io/api/news?id=06d3672ffde6088cdd59e1e3da1b5462b2a0ae5f78814f5bf0b5420799ff8cce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Both companies are unprofitable and burning cash, but their paths to scale, and valuations, tell strikingly different stories.",
                "category": "company",
                "datetime": 1791661802,
                "headline": "Redwire vs. Rocket Lab: Which Industrials Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142793630,
                "url": "https://finnhub.io/api/news?id=14753be7d11d894ea51502d0db63d4c87b93bf7469769ea8a496fffe204de0e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.",
                "category": "company",
                "datetime": 1791649982,
                "headline": "Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142772223,
                "url": "https://finnhub.io/api/news?id=d7341b07311e0a7aadb936df0d126442fa321eed83f51e517867f131ac1fb044",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Gilead Sciences (GILD) generated free cash flow equal to 7.1% of its market value over the last twelve months. The median S&P 500 company yielded just 4.5% over the same period. A yield that high means one of two things: the business is either trading at a steep discount, or the market expects it to shrink. So why are investors paying so little for Gilead's cash.",
                "category": "company",
                "datetime": 1791593224,
                "headline": "Why Is Everyone Ignoring Gilead Stock's High Cash Yield?"
              },
              {
                "id": 142766263,
                "url": "https://finnhub.io/api/news?id=8ec035baab86cf7792f8c473ed9d920f88a6b869215a9474bf070dbaea0125ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Merck (MRK) stock returned 69.6% over the year to October 8, 2026, against 16.3% for the S&P 500. The gain built up over a year of drug approvals and clinical trial results, arriving just as the company prepares for the patent loss on Keytruda, its top-selling drug. So what did Merck show investors over those twelve months.",
                "category": "company",
                "datetime": 1791569538,
                "headline": "Does The Move In Merck Stock Change Anything?"
              },
              {
                "id": 142765273,
                "url": "https://finnhub.io/api/news?id=47173bc504c3fb1af7e77e0a591d37acbd67138829b9392f495a46c5f62f2c37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself.",
                "category": "company",
                "datetime": 1791567949,
                "headline": "Pfizer’s Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning"
              },
              {
                "id": 142765373,
                "url": "https://finnhub.io/api/news?id=e0a836e28706d2bde28d57ad02ce600b67348a228f81549f9b31f82c57cd9d77",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (NYSE:BMY) reported new Phase 3 EXCALIBER-RRMM data for its Zenbexus combination in relapsed or refractory multiple myeloma. The regimen achieved significant progression free survival in the trial, alongside high minimal residual disease negative complete response rates. EXCALIBER-RRMM results are being positioned as supportive evidence for potential accelerated approval of Zenbexus in this blood cancer setting. The strong progression free survival and MRD negative...",
                "category": "company",
                "datetime": 1791566121,
                "headline": "What Could Bristol Myers Squibb (BMY) Phase 3 Myeloma Data Mean For Investors?"
              },
              {
                "id": 142791211,
                "url": "https://finnhub.io/api/news?id=8515c8cafa622c1ba55b6a4727cf33da0134590c035e2163865fea16ff57ffd7",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1791552910,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 142759459,
                "url": "https://finnhub.io/api/news?id=e29368a8ccb2b9a787320d546fbe413404f6542cd74721d6c28b2806389e5483",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.",
                "category": "company",
                "datetime": 1791542110,
                "headline": "2 Profitable Stocks to Target This Week and 1 We Find Risky"
              },
              {
                "id": 142739710,
                "url": "https://finnhub.io/api/news?id=ff2eadf86d47af8338f0f782fe2d50e7e67c0aa90a27adc58e9343384e4eb3d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.",
                "category": "company",
                "datetime": 1791507792,
                "headline": "Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142738442,
                "url": "https://finnhub.io/api/news?id=f75e26b0729c5bff9494c60706fdff46e2e8753e7576109a0837be7c38c177d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer (PFE) stock has returned 17.5% over the past three months, easily outpacing the 3.7% return for the S&P 500. The board also just declared its 352nd quarterly dividend in a row. That reliable payout may be why many investors hold the shares, yet on Pfizer's latest earnings call, management was asked what it would take to cut that dividend. So what is Pfizer's management preparing for.",
                "category": "company",
                "datetime": 1791506167,
                "headline": "Should You Be Worried About Pfizer Stock?"
              },
              {
                "id": 142736104,
                "url": "https://finnhub.io/api/news?id=bff74f60d6f2160c55eb02e7e452a8c1637af7ee73d80472a98ad1b017bcc0e4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Regeneron Pharmaceuticals (REGN) stock currently trades at 17.6 times earnings. That represents a notable discount to the 21.5 multiple of the median S&P 500 company. The shares have lost 4.1% over the past six months, trailing the 15.7% return of the broader index. Over twelve months, however, the stock returned 27% against the index's 17.1%. A valuation this low suggests investors are either overlooking a sound drug maker or pricing in underlying problems. So how healthy is the business you wo",
                "category": "company",
                "datetime": 1791505165,
                "headline": "What Is Going On With Regeneron Stock?"
              },
              {
                "id": 142731136,
                "url": "https://finnhub.io/api/news?id=dbac7f7a40febdb48ecf58e0a5329fd219188f485b587d02ef6c690fab361a48",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BMS’s Zenbexus gained FDA approval based on a previous primary endpoint being achieved in the same trial.",
                "category": "company",
                "datetime": 1791478502,
                "headline": "BMS’s Zenbexus meets PFS endpoint in pivotal multiple myeloma trial"
              },
              {
                "id": 142731137,
                "url": "https://finnhub.io/api/news?id=1b586b9519ff14036d32ca2deefc32131df08a05417995d3a5e48cf4e6c0aafc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
                "category": "company",
                "datetime": 1791472202,
                "headline": "Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?"
              },
              {
                "id": 142729808,
                "url": "https://finnhub.io/api/news?id=cfecdba559d9188cb658eba2eedbca983c8d2b838d0d76a1bf579ad858f1f60f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "ABBV's Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.",
                "category": "company",
                "datetime": 1791470820,
                "headline": "AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer"
              },
              {
                "id": 142727204,
                "url": "https://finnhub.io/api/news?id=0777919541fde067a3ae7f2057a4e37174b1a46ec3889aa06a812dc2cfa4d84e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Amgen (AMGN) stock has returned 44% over the past twelve months, easily outpacing the 17.1% gain for the S&P 500. Investors looking at that rally might question what catalysts remain to push shares higher. One candidate is an experimental therapy that is not yet on the market, and executives say its development is progressing rapidly. So what is that drug, and how far along is it.",
                "category": "company",
                "datetime": 1791464604,
                "headline": "What Would It Take For Amgen Stock To Move Higher?"
              },
              {
                "id": 142727216,
                "url": "https://finnhub.io/api/news?id=f68d824c4d00c5a5a7946f0efd5425f549a1c8a9ac48b5efaa10b122b81328b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Complimentary executive passes remain available for qualified CIOs, CISOs, CTOs, Chief Digital Officers, Chief AI Officers and other senior technology executivesFAIRFIELD, Conn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- More than 100 CIOs, CISOs, CTOs, Chief Digital Officers and other senior technology executives from leading organizations across Connecticut, Westchester County, New York City and the Northeast have registered for HMG Strategy's 19th Annual Greenwich C-Level Technology Leadership Summit",
                "category": "company",
                "datetime": 1791462600,
                "headline": "More Than 100 Technology Leaders Registered for HMG Strategy's 19th Annual Greenwich C-Level Technology Leadership Summit on October 15"
              },
              {
                "id": 142762499,
                "url": "https://finnhub.io/api/news?id=4c0bd783ed7f4fa99ded5b52620245d19cae34491b8d4fa7b320c2ede22c50e4",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/08/Rueil-malmaison--France---August-13--202.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Bristol Myers Squibb reports positive Phase 3 trial data, showing ZENBEXUS cuts the multiple myeloma progression risk by 51%.",
                "category": "company",
                "datetime": 1791462466,
                "headline": "Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%"
              },
              {
                "id": 142726147,
                "url": "https://finnhub.io/api/news?id=c7a65aa69926ee7e6305636cef5ad80a2d264e606387a0e4d1001d6956923126",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb (BMY) said Thursday that a phase 3 study evaluating Zenbexustm in combination w",
                "category": "company",
                "datetime": 1791460526,
                "headline": "Bristol Myers Squibb's Zenbexus Combination Shows Improved Progression-Free Survival in Phase 3 Trial"
              },
              {
                "id": 142726148,
                "url": "https://finnhub.io/api/news?id=d30830bb5dd382b73acfe5c9b6fd258e94c60995fb1967c207cc326edb02f4f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., October 08, 2026--Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior...",
                "category": "company",
                "datetime": 1791457140,
                "headline": "Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3..."
              },
              {
                "id": 142728291,
                "url": "https://finnhub.io/api/news?id=2c759e2e8075bcd7a9364176b26189f541fcdd9bc3f365ae6594e08455ec1191",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and lowers the price target from $59 to $53.",
                "category": "company",
                "datetime": 1791441711,
                "headline": "Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53"
              },
              {
                "id": 142701425,
                "url": "https://finnhub.io/api/news?id=e2f0bfd9e6f319752830403a4bdb209f9a3cd2a7911912311584e926744f9daf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "If you are looking for yield and can think long-term, you'll want to consider Bristol Myers Squibb and Realty Income today.",
                "category": "company",
                "datetime": 1791416100,
                "headline": "2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One)"
              },
              {
                "id": 142701310,
                "url": "https://finnhub.io/api/news?id=be0a7e3fa760ed5f0a5c52227739c617a8ce6b41a96fbf2c446e8d620797eaa5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Exelixis (EXEL) stock has returned 46% over the past twelve months, compared with 17.8% for the S&P 500. The company has aggressively repurchased its own stock, reducing its total share count by 21% over the last three years. Because fewer shares remain in circulation, each one lays claim to a larger slice of the profit. So how much is that buyback adding to each Exelixis share you own.",
                "category": "company",
                "datetime": 1791414880,
                "headline": "Is Exelixis Stock Engineered To Make You Money?"
              },
              {
                "id": 142701040,
                "url": "https://finnhub.io/api/news?id=133762d44d4e6a72c3e9a578f3dff5ac29ad0884b13d807f18613432a747363e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160008492/image_2160008492.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb is reiterated as a buy, offering attractive valuation and a high 4.23% dividend yield. Click to read more about the BMY stock.",
                "category": "company",
                "datetime": 1791400640,
                "headline": "Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An Opportunity"
              },
              {
                "id": 142699368,
                "url": "https://finnhub.io/api/news?id=844580da2d37328ae230aab32ca06289ade7fbdcd838d97dc779f53af701318d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indications offering further upside.",
                "category": "company",
                "datetime": 1791394200,
                "headline": "Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?"
              },
              {
                "id": 142697131,
                "url": "https://finnhub.io/api/news?id=ae1226bd9094f32438cd7331bcb6012f816a512141a53bdc5f6cebc33fd261be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.",
                "category": "company",
                "datetime": 1791386460,
                "headline": "Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial"
              },
              {
                "id": 142697097,
                "url": "https://finnhub.io/api/news?id=aa96bd438f629403236b9e3e1bb680028b711cd0bbfc2008e5c540f0ef96ca1f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "A fat dividend yield means nothing if the cash runs dry before the check clears. These five companies show wildly different margins of safety, and one of them barely cleared the bar last quarter.",
                "category": "company",
                "datetime": 1791382529,
                "headline": "5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong"
              },
              {
                "id": 142727689,
                "url": "https://finnhub.io/api/news?id=111a5acaac46f167d1961c88b8fc1c3249af2292e699a5d3873804e67dbd074c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/07/Tempus-AI-Logo-On-Mobile-Phone.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.",
                "category": "company",
                "datetime": 1791380692,
                "headline": "Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure"
              },
              {
                "id": 142697075,
                "url": "https://finnhub.io/api/news?id=c419420fe2d5322586a9d665384b886c96b7108bad7e2b7261ec8665071c9055",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "RDW expands microgravity applications into pharmaceutical research, creating potential revenue streams through research and licensing.",
                "category": "company",
                "datetime": 1791380520,
                "headline": "Can Redwire's Microgravity Pharma Work Create New Revenue Streams?"
              },
              {
                "id": 142694797,
                "url": "https://finnhub.io/api/news?id=9341753067ec7303a18b5dc32038dedf342625a5fc4b7bc46d2a2eb38e760948",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "MOUNTAIN VIEW, Calif., October 07, 2026--At AeraHUB 26, Aera Technology’s global decision intelligence event, enterprises share how they’re applying AI to the decisions that run the business.",
                "category": "company",
                "datetime": 1791378000,
                "headline": "AeraHUB 26 NYC Brings the Decision-Centric Enterprise to Life"
              },
              {
                "id": 142693956,
                "url": "https://finnhub.io/api/news?id=a8036f24f37b5726e836e430be96095a04a688a9180eb569820e4af3452a7012",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (BMY) just secured an expanded FDA approval for Camzyos in symptomatic obstructive hypertrophic cardiomyopathy, including eligible pediatric patients. That fresh label update is the starting point for reassessing the stock. The fresh Camzyos label lands as Bristol-Myers Squibb’s share price has climbed 11.47% year to date to US$59.59, even though the 30-day share price return is down 10.82%. Meanwhile, a 39.37% total shareholder return over the past year signals stronger...",
                "category": "company",
                "datetime": 1791371466,
                "headline": "Bristol Myers Squibb (BMY) Secured A Camzyos Label Expansion, Is It Still Undervalued?"
              },
              {
                "id": 142728293,
                "url": "https://finnhub.io/api/news?id=cf257841f39aa183a8abaf52b7b128870febe449becd52d7195c24d070ceb824",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Morgan Stanley  analyst Terence Flynn   maintains Bristol-Myers Squibb (NYSE:BMY) with a Underweight and raises the price target from $40 to $41.",
                "category": "company",
                "datetime": 1791369041,
                "headline": "Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Raises Price Target to $41"
              },
              {
                "id": 142667789,
                "url": "https://finnhub.io/api/news?id=3d9f27ba65045e073d7df40e885aa0da96d9921465245b465af5516329f40987",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "New research finds growing prescriber adoption and enthusiasm for TYK2 differentiation, while limited experience, access friction, and questions around joint efficacy temper early launch momentum.Exton, PA, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Five months into the U.S. launch of Bristol Myers Squibb’s (BMS) Sotyktu (deucravacitinib) for psoriatic arthritis (PsA), rheumatologists are increasingly adding the oral TYK2 inhibitor to their treatment armamentarium. Yet, new research from Spherix Global I",
                "category": "company",
                "datetime": 1791314700,
                "headline": "Sotyktu Gains Ground in Psoriatic Arthritis, but Rheumatologists Remain Selective as Its Role in the Treatment Algorithm Takes Shape, According to Spherix Global Insights"
              },
              {
                "id": 142667907,
                "url": "https://finnhub.io/api/news?id=c6b897354c57e6133ea7e0f83655aab4272296ea5495a0d9305ca0ac8607f81b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689585487/image_1689585487.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb is a Hold as replacing lost revenue from Eliquis and Opdivo presents a significant challenge. Click here to read this BMY stock update.",
                "category": "company",
                "datetime": 1791302210,
                "headline": "Bristol-Myers Squibb: Patent Cliff Is Still A Problem"
              },
              {
                "id": 142663208,
                "url": "https://finnhub.io/api/news?id=a62ddf37a7fc41526d48b3d07c1fa82eddce11f1cf07e5af54b8728112b784cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "SEATTLE, October 06, 2026--Lila Biologics (\"Lila Bio\"), an AI-driven targeted radiopharmaceutics company, today announced that Kimberly Ma, M.S., has been appointed Chief Development Officer. Ms. Ma brings more than 20 years of experience in oncology drug development including her recent leadership roles at Abdera Therapeutics and RayzeBio. At Abdera, Ms. Ma served as SVP, Clinical Development & Operations and on the Executive Committee supporting development of the lead clinical programs. Prior",
                "category": "company",
                "datetime": 1791289800,
                "headline": "Lila Bio Expands Leadership Team with Kimberly Ma, M.S., as Chief Development Officer"
              },
              {
                "id": 142648417,
                "url": "https://finnhub.io/api/news?id=00d1fd6b292be740f72f0ba74afb6fbdac167dd7671d25c1db2921ac9df67890",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Dollar General, Bristol-Myers Squibb and Equinor ASA have been highlighted in this Screen of The Week article.",
                "category": "company",
                "datetime": 1791262080,
                "headline": "Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA"
              },
              {
                "id": 142668828,
                "url": "https://finnhub.io/api/news?id=7b8568399b0804bb9153f4054d73dd2349add4e50cbc53af59a604c99fef2622",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is in an interesting spot. The company is still one of the biggest names in pharmaceuticals, but its investment story is changing. Some of its older blockbuster drugs are facing patent and generic pressure. At the same time, newer medicines are starting to do more of the heavy lifting. That transition […]",
                "category": "company",
                "datetime": 1791238742,
                "headline": "Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Here’s Why it Matters"
              },
              {
                "id": 142638288,
                "url": "https://finnhub.io/api/news?id=4796f000e83db0803c6b2ad30c002a2fc93fd2d01cc72622994706b14f78ea94",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1791227101,
                "headline": "Uncover the latest developments among S&P500 stocks in today's session."
              },
              {
                "id": 142637485,
                "url": "https://finnhub.io/api/news?id=67961b010b1f3caecc8f221b133dc532a01b4d12e570aa9d8e37f37167ccb5a0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.",
                "category": "company",
                "datetime": 1791218101,
                "headline": "Which S&P500 stocks are moving on Monday?"
              },
              {
                "id": 142637861,
                "url": "https://finnhub.io/api/news?id=33675210c81007c16fec9e6658fab67e6783ea790d1517d01350184f26a4fc7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "CAMBRIDGE, England, October 05, 2026--CN Bio, a leading Organ-on-a-chip (OOC) company de-risking drug discovery and development pipelines by enabling earlier, more confident decision-making, today announced the full scientific programme for the 2026 ‘From Insight to Decision’ e-Symposium. Taking place on the 2nd and 8th of December, the event will feature expert-led sessions offering practical, real-world guidance on OOC use within existing R&D strategies.",
                "category": "company",
                "datetime": 1791216720,
                "headline": "CN Bio Announces Expert Speaker Line-Up and Scientific Program for Inaugural Organ-on-a-Chip e-Symposium"
              },
              {
                "id": 142636958,
                "url": "https://finnhub.io/api/news?id=ab4659337d39646155249ca4369a9dd04e0c14c38cc19cb58d0a59f25a6e5d16",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BMY vs. ARGX: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1791211204,
                "headline": "BMY or ARGX: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142636959,
                "url": "https://finnhub.io/api/news?id=91f767845fca233e847d58639711184475fbaff8d55aab80b5edcbe5f7e165bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Investing.com -- Shares of Bristol-Myers Squibb Co. (NYSE: BMY) fell 2.5% in premarket trading after Leerink Partners downgraded the pharmaceutical giant from Outperform to Market Perform, citing growing skepticism surrounding key candidates in the company’s drug development pipeline.",
                "category": "company",
                "datetime": 1791208739,
                "headline": "Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt"
              },
              {
                "id": 142359355,
                "url": "https://finnhub.io/api/news?id=278334f451c48e13a3bad1a2f529fd8d10e1e1956c735cccaeaaf16a629e6790",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1791207852,
                "headline": "Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls"
              },
              {
                "id": 142635192,
                "url": "https://finnhub.io/api/news?id=3c616f98a34f8a7a00bf65936140dba6e651445d51af223413a78a45199e562b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.",
                "category": "company",
                "datetime": 1791204004,
                "headline": "Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?"
              },
              {
                "id": 142635194,
                "url": "https://finnhub.io/api/news?id=9d62959f4ddcffec2f0154e9eb1c2ccfe92e651c066dce87257fbc72d8b307bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Dollar General, Bristol-Myers and Equinor stand out after broker rating upgrades, backed by projected earnings growth and resilient U.S. equity markets.",
                "category": "company",
                "datetime": 1791202860,
                "headline": "3 Stocks With Broker Rating Upgrades Amid Resilient Equity Markets"
              },
              {
                "id": 142634313,
                "url": "https://finnhub.io/api/news?id=817fbff19a109e01a0b66c0c91a8f2da0d50bee0af0d803e874e2b66e5db399b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.",
                "category": "company",
                "datetime": 1791199860,
                "headline": "3 Value Stocks We Steer Clear Of"
              },
              {
                "id": 142634312,
                "url": "https://finnhub.io/api/news?id=6aad506b9c6692e3a9776f45e1c94012135f5069290f7767df09b1e29f3f3012",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Second-Year Champions in Care Campaign Introduces $1 Million Community Grant Program for Medically Underserved CommunitiesPRINCETON, NJ / ACCESS Newswire / October 5, 2026 / Originally published by Bristol Myers SquibbBristol Myers Squibb (NYSE:BMY) recently announced the expansion of Champions in Care, the company's initiative honoring healthcare professionals (HCPs), first launched in 2025. Now in its second year, the campaign builds on its inaugural effort that celebrated HCPs across therapeu",
                "category": "company",
                "datetime": 1791199740,
                "headline": "Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement"
              },
              {
                "id": 142634275,
                "url": "https://finnhub.io/api/news?id=79e8a4a1c0aeae961e7785bb87893534635e3e9d7ea15bb2d19eaa65fabaa588",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or a ceiling, and the answer hinges on a single pipeline deal that could reshape the obesity drug race.",
                "category": "company",
                "datetime": 1791198942,
                "headline": "Pfizer’s Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside"
              },
              {
                "id": 142637570,
                "url": "https://finnhub.io/api/news?id=19d1d63ae1aa1cc65eb529ab35dabf65b41135c0f9cee3628be02e14fa1e568b",
                "image": "https://image.cnbcfm.com/api/v1/image/108372555-17912086801791208677-48806376512-1080pnbcnews.jpg?v=1791208678&w=1920&h=1080",
                "source": "CNBC",
                "related": "BMY",
                "summary": "CNBC’s Jim Cramer explains why he is keeping an eye on this pharmaceutical company",
                "category": "company",
                "datetime": 1791194402,
                "headline": "Cramer’s Stop Trading: Bristol Myers"
              },
              {
                "id": 142634841,
                "url": "https://finnhub.io/api/news?id=decbe7600904403e99096d6d7fb4d9c2fa327e5bfe66f161e8ceb1c59eea0f9e",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Leerink Partners  analyst David Risinger   downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform and lowers the price target from $73 to $59.",
                "category": "company",
                "datetime": 1791191074,
                "headline": "Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59"
              },
              {
                "id": 142623564,
                "url": "https://finnhub.io/api/news?id=0239c0fdaed29155b6cf30b792945e313c370a2fe0edfe251cd76905a7b7f109",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2270977838/image_2270977838.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "BioNTech pivots from Covid windfall to oncology with 33 trials and $19B cash; key pumitamig data post-2028. Click for more on BNTX stock.",
                "category": "company",
                "datetime": 1791107051,
                "headline": "BioNTech SE: Moving Past Covid"
              },
              {
                "id": 142618515,
                "url": "https://finnhub.io/api/news?id=acedf7ae2285dee254393203d1a2bcb489bd28de60e87f8af56da1e7e1c98e0a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie Inc. (NYSE:ABBV) closed at $262.82 on October 2, and Bristol Myers Squibb Company (NYSE:BMY) at $61.15. Both spent the last few years doing the same difficult thing. Replacing a drug that was about to lose its patent with something new, before the revenue disappeared. AbbVie is widely seen as having pulled it off and […]",
                "category": "company",
                "datetime": 1791081989,
                "headline": "AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?"
              },
              {
                "id": 142608307,
                "url": "https://finnhub.io/api/news?id=72573309fb635ce9ae722ac179f728b7ef0ba875a0fd0d38393a29a44bc802b0",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "BMY",
                "summary": "BMY passes ChartMill’s Best Dividend Stocks screen with a 4.58% yield, but payout sustainability and falling EPS warrant income-investor caution.",
                "category": "company",
                "datetime": 1791018055,
                "headline": "Bristol-Myers Squibb (NYSE:BMY) Dividend Quality: High Yield, Sustainability Concerns"
              },
              {
                "id": 142605983,
                "url": "https://finnhub.io/api/news?id=08933cd77a66143ad37129ada1da7023c5cbc605081de34ceab65393070731df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.",
                "category": "company",
                "datetime": 1791012000,
                "headline": "Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy?"
              },
              {
                "id": 142590917,
                "url": "https://finnhub.io/api/news?id=920c44275ae79e66ba1c8fd085ce26c3b5971f33c97aa21e115c82479e02a728",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.",
                "category": "company",
                "datetime": 1790947320,
                "headline": "Agios' Growth Story Hinges on Mitapivat's Commercial Expansion"
              },
              {
                "id": 142588552,
                "url": "https://finnhub.io/api/news?id=b3d3036097a4ba692409a8cae4694ed2309a40814a5045d592dd8e28ac411ba7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.",
                "category": "company",
                "datetime": 1790943300,
                "headline": "Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?"
              },
              {
                "id": 142585466,
                "url": "https://finnhub.io/api/news?id=67bda7f26ae04d0d3f35078b1e3e515457b65d707cb614ee0369159ab7b04c5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer's management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal.",
                "category": "company",
                "datetime": 1790936840,
                "headline": "How Has Pfizer's Story Changed?"
              },
              {
                "id": 142563714,
                "url": "https://finnhub.io/api/news?id=e98e6cb8cdda4ddef333d043a63b0f58a5549656408252b35331ef9926a27d67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.",
                "category": "company",
                "datetime": 1790894462,
                "headline": "AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142561926,
                "url": "https://finnhub.io/api/news?id=8e2424c95f041f5610a0f547cceaa694d28197a94061c916c6df88ee99a6acd2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.",
                "category": "company",
                "datetime": 1790882102,
                "headline": "Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale"
              },
              {
                "id": 142557736,
                "url": "https://finnhub.io/api/news?id=e1273e66c53cdbc9108c6bdb67d056d25e1b2fdfd55a80193cb3c97ccc0bfdc9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Four dividend stocks from Philip Morris to JPMorgan Chase have ex-dates landing within days, and missing the cutoff means the payout goes to the seller. The clock is already running.",
                "category": "company",
                "datetime": 1790858725,
                "headline": "5 High-Yield Dividends With Ex-Dates Days Away: Buy Before the Window Closes"
              },
              {
                "id": 142524143,
                "url": "https://finnhub.io/api/news?id=9f43c98b4543e659a0f92a30884c76890d979b44979a7ee0a7d1fb8a88de1430",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., September 30, 2026--U.S. FDA Approves Expanded Indication for BMS’s CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients",
                "category": "company",
                "datetime": 1790803920,
                "headline": "U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*"
              },
              {
                "id": 142522098,
                "url": "https://finnhub.io/api/news?id=f535300bd9fba98cba15f470f8dad56b9e165b770d71a4da4706c86efa7c36c5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Investors seeking a high yield and stable fundamentals in the healthcare sector need look no further than Bristol Myers Squibb.",
                "category": "company",
                "datetime": 1790787959,
                "headline": "This Pharma Giant Has The Right Medicine For Income Investors"
              },
              {
                "id": 142522097,
                "url": "https://finnhub.io/api/news?id=47807cda8396deb39ee7602b7f6c0c0fe1467cdb52fce23340e23371afa2fee7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the drug was to blame.",
                "category": "company",
                "datetime": 1790785320,
                "headline": "Bristol Myers trial revisions shake confidence in new class of fibrosis drugs"
              },
              {
                "id": 142521424,
                "url": "https://finnhub.io/api/news?id=5e05a55b5368eb632e6c4ff003e78f91b2efdf0eff472e1cb61daa068c6c728a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Fortune today announced an additional group of speakers for the Fortune 500 Innovation Forum, November 16–17, 2026, in Detroit, Michigan. The newly confirmed leaders will join CEOs, entrepreneurs, policymakers, investors, and civic innovators from across the country for conversations about the forces reshaping American business, technology, work, manufacturing, and prosperity.",
                "category": "company",
                "datetime": 1790784300,
                "headline": "FORTUNE ANNOUNCES ADDITIONAL POWERHOUSE SPEAKERS AND SPONSORS AT FORTUNE 500 INNOVATION FORUM, NOV. 16-17 IN DETROIT"
              },
              {
                "id": 142520963,
                "url": "https://finnhub.io/api/news?id=ce89da1e22029a72629e72abf8b7ec36fdd761aeffd8645e25e0bf56e44c5318",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff on its biggest cash generator puts that streak on a collision course with reality in 2027.",
                "category": "company",
                "datetime": 1790783153,
                "headline": "Bristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow Metric"
              },
              {
                "id": 142520938,
                "url": "https://finnhub.io/api/news?id=d1eb4315fad523961856dae046c32d7afc414b02c0c8ed1777d096c67b742be6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Key TakeawaysPfizer yields about 6% and Bristol Myers about 4%, and each has more than $22 billion of revenue from drugs losing U. S.",
                "category": "company",
                "datetime": 1790782483,
                "headline": "PFE vs. BMY: Each Faces a $22 Billion+ Patent Cliff. One Dividend Looks Much Safer"
              },
              {
                "id": 142520808,
                "url": "https://finnhub.io/api/news?id=72a16884875e8205de3652d0399aae55c3f3a4b916c99485ad73dc7a499774f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.",
                "category": "company",
                "datetime": 1790782145,
                "headline": "Are You Overpaying For Pfizer Stock Versus Its Rivals?"
              },
              {
                "id": 142558379,
                "url": "https://finnhub.io/api/news?id=387ac44e3fd9015d0161caad130828554928bb0ac71139a7664b29938503581e",
                "image": "",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-improve-functional-capacity-and-symptoms-children-rare-inherited-heart",
                "category": "company",
                "datetime": 1790779692,
                "headline": "FDA Approves Bristol Myers Squibb's Camzyos As First Treatment For Children With Obstructive Hypertrophic Cardiomyopathy Weighing At Least 30 kg"
              },
              {
                "id": 142520809,
                "url": "https://finnhub.io/api/news?id=76d46d09777c71c504574fbb4fc04c17977db7ccfaa9d0806d18f0f7f44a6972",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.",
                "category": "company",
                "datetime": 1790779413,
                "headline": "What Is Merck Stock's Biggest Opportunity?"
              },
              {
                "id": 142522477,
                "url": "https://finnhub.io/api/news?id=068463668d2212d15e97edb2e63a51e7484ed7de5b6ef55dc9fed6e8a924c39a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2297545866/image_2297545866.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Lexicon Pharmaceuticals, Inc. upgraded to Buy as multiple near-term catalysts emerge across its pipeline. Click for this updated look at LXRX.",
                "category": "company",
                "datetime": 1790779100,
                "headline": "Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More"
              },
              {
                "id": 142517032,
                "url": "https://finnhub.io/api/news?id=36ed3d72e4068a8b714faf41b59c9afdbdc8b42a4f296c513b9bce15a4ec7fdd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1790769603,
                "headline": "Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know"
              },
              {
                "id": 142520370,
                "url": "https://finnhub.io/api/news?id=6e9398ea3aad6a4279594b8edc0f3916b3eca6d970b80b9088aaff22f57dae72",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/30/Novo-Nordisk-Advertising-Logo-On-Facade-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.",
                "category": "company",
                "datetime": 1790764142,
                "headline": "Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide (CORRECTED)"
              },
              {
                "id": 142512602,
                "url": "https://finnhub.io/api/news?id=37a1437e25f832cb49b993def235bdaf39695b5184d86e5c9fd31392f0d35df6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026",
                "category": "company",
                "datetime": 1790758020,
                "headline": "CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J"
              },
              {
                "id": 142508684,
                "url": "https://finnhub.io/api/news?id=a5d84d4819342ebb2ca0cc213ab75597959c5f54b0bae7a509182e56d029a12b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "In September 2026, Bristol Myers Squibb reported first-time, pivotal Phase 3 EXCALIBER-RRMM data showing ZENBEXUS (iberdomide) plus daratumumab and dexamethasone produced a statistically significant, clinically meaningful improvement in minimal residual disease–negative complete responses versus a standard daratumumab-based regimen in relapsed or refractory multiple myeloma. This MRD-focused outcome is particularly important because it informs the accelerated approval pathway for ZENBEXUS...",
                "category": "company",
                "datetime": 1790730497,
                "headline": "How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors"
              },
              {
                "id": 142502204,
                "url": "https://finnhub.io/api/news?id=dad28c5abdd129fdb1e804b20e2b6ae25777b536ab3328c866194994463de7a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb trades at a fraction of Eli Lilly's valuation while generating substantial free cash flow, but concentration risk and explosive growth tell very different stories.",
                "category": "company",
                "datetime": 1790721721,
                "headline": "Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142500490,
                "url": "https://finnhub.io/api/news?id=8427ee555be225ae58ea52bd6fe4329e91d6f3e5b605a515e212cd597de3fe67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (NYSE:BMY) reported pivotal Phase 3 EXCALIBER-RRMM data for ZENBEXUS in relapsed or refractory multiple myeloma. The Phase 3 trial showed a clinically meaningful advantage in MRD-negative complete response rates versus standard therapy. The first full readout of EXCALIBER-RRMM highlights potential clinical and commercial relevance for ZENBEXUS in a crowded myeloma treatment field. The MRD-negative complete response results from EXCALIBER-RRMM are important, but investors...",
                "category": "company",
                "datetime": 1790708805,
                "headline": "Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial"
              },
              {
                "id": 142499276,
                "url": "https://finnhub.io/api/news?id=c8d8f4e81edd7b59660f888999a6796d6a5cde9437dc254aefeab9dab2621342",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors.",
                "category": "company",
                "datetime": 1790702400,
                "headline": "Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now"
              },
              {
                "id": 142498195,
                "url": "https://finnhub.io/api/news?id=4d505074b60a93975e3f9d5d56eaae73daf519072275e4154396f4bc2ec03b25",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.",
                "category": "company",
                "datetime": 1790694239,
                "headline": "AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck"
              },
              {
                "id": 142495912,
                "url": "https://finnhub.io/api/news?id=ea176b460b0d6d7c5be2b1e3047618949f973dc09d17c57b654d849c56b07f57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.",
                "category": "company",
                "datetime": 1790691900,
                "headline": "Inside the AstraZeneca Deal That Could Send Summit Therapeutics Stock Up 126%"
              },
              {
                "id": 142495913,
                "url": "https://finnhub.io/api/news?id=b5bb0804b9d241ad2bdc8e3648487180c38dca6e188f0717ccfa40401e82ed1e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.",
                "category": "company",
                "datetime": 1790689210,
                "headline": "AstraZeneca Pays $2 Billion To Get Into High-Profile Cancer Space"
              },
              {
                "id": 142518082,
                "url": "https://finnhub.io/api/news?id=be3c3af3788540a9989417f7955215345728cfaa9e7596aaf52e032476a5ee18",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/29/Novo-Nordisk-Advertising-Logo-On-Facade-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BMY",
                "summary": "Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.",
                "category": "company",
                "datetime": 1790686485,
                "headline": "Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide"
              },
              {
                "id": 142496029,
                "url": "https://finnhub.io/api/news?id=e108eee7413eecc464685d3600cab6c9208684f4ecff07fac5c03575dc405c18",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
                "category": "company",
                "datetime": 1790683802,
                "headline": "How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks"
              },
              {
                "id": 142495024,
                "url": "https://finnhub.io/api/news?id=779226fae6ca70292a812a76ecd8a9451d34091b63c78e44a988680a9b74093d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb has delivered a 51.6% gain over the past year, helped by fresh drug data and a steadily expanding pipeline, which puts fresh focus on what investors are really paying for its future cash flows today. With the stock recently closing at US$63.88, the key issue is whether that price still lines up with what the company’s current and prospective cash generation can support. Bristol-Myers Squibb’s 51.6% one year return puts meaningful expectations into the share price, so the...",
                "category": "company",
                "datetime": 1790676377,
                "headline": "Bristol Myers Squibb (BMY) Stock Trades Below Fair Value As Caution Lingers"
              },
              {
                "id": 142488930,
                "url": "https://finnhub.io/api/news?id=5b2d9c69520a3399fbbf8379f6b848f29c71a1d1efa5815badb5e7fbd19e0596",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.",
                "category": "company",
                "datetime": 1790674860,
                "headline": "3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation"
              },
              {
                "id": 142489065,
                "url": "https://finnhub.io/api/news?id=ea813dd1e58f509bdd317124bf3ae6c6c0687064350e55cb15e626ab5cb12a69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.",
                "category": "company",
                "datetime": 1790673541,
                "headline": "1 Cash-Producing Stock to Keep an Eye On and 2 Facing Challenges"
              },
              {
                "id": 142479811,
                "url": "https://finnhub.io/api/news?id=0714d67165220c8b178a13db884659ebba3b5e3fa2614bf91c2118312f3effd4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2244980373/image_2244980373.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.",
                "category": "company",
                "datetime": 1790649185,
                "headline": "Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough"
              },
              {
                "id": 142474022,
                "url": "https://finnhub.io/api/news?id=7fe7638e1a27211070fb93cd5c2527370b739a29b9d7e7c48037142f6719e3cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "On September 25, Bristol-Myers Squibb Company (NYSE:BMY) announced milestone results from its Phase 3 EXCALIBER-RRMM trial evaluating Zenbexus in combination with daratumumab and dexamethasone (ZDd) for relapsed or refractory multiple myeloma. At a median follow-up of 15.7 months across 420 patients, ZDd demonstrated a statistically significant improvement in minimal residual disease (MRD)-negative complete response rates […]",
                "category": "company",
                "datetime": 1790642608,
                "headline": "Could Bristol-Myers Squibb (BMY)’s New Myeloma Data Reshape its Growth Outlook?"
              },
              {
                "id": 142471333,
                "url": "https://finnhub.io/api/news?id=32d34337814034fe8149ead79ef4a35c96ee77f1dabff06ee5527a307bf4762b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "On September 8, Bristol-Myers Squibb Company (NYSE:BMY) announced positive Phase 2 results from its registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel (arlo-cel) in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM). The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful overall response rate (ORR) alongside strong complete response rates […]",
                "category": "company",
                "datetime": 1790629278,
                "headline": "Bristol-Myers Squibb (BMY) is Building its Next Growth Engine. Can It Replace Lost Revenue?"
              },
              {
                "id": 142470205,
                "url": "https://finnhub.io/api/news?id=49b660d989fd3bd8c621fd4697d8ecaecc3b5702e8ef6817407f5d2420c581f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "If you own Merck (MRK) stock, the number to watch is the sales of one cancer drug family. KEYTRUDA family sales were $8.4 billion in the second quarter of 2026. That was about half of Merck's $16.6 billion in quarterly revenue. Management now expects KEYTRUDA’s U.S. growth to moderate, raising questions about whether the stock's recent run has fully priced in the transition.",
                "category": "company",
                "datetime": 1790618927,
                "headline": "What Are Merck Stock Investors Overlooking?"
              },
              {
                "id": 142520966,
                "url": "https://finnhub.io/api/news?id=c6966d13473db7f8d144ca3ac42ae2bb1bbd0971ef0ae15c34c3dd8bd63ca9bb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway.",
                "category": "company",
                "datetime": 1790600940,
                "headline": "Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension"
              },
              {
                "id": 142463850,
                "url": "https://finnhub.io/api/news?id=e9375d8facd15bb5f07384fd833ba852b1f0f79dbbaf7da95c0ce3ebd4b18095",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Originally published by the Bristol Myers Squibb FoundationNORTHAMPTON, MA / ACCESS Newswire / September 28, 2026 / Francis Kwoba is a 68-year-old retired policeman from Bungoma County, Kenya. During one of his usual morning runs, he experienced a sudden sharp pain in his chest.",
                "category": "company",
                "datetime": 1790594940,
                "headline": "Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa"
              },
              {
                "id": 142463849,
                "url": "https://finnhub.io/api/news?id=727319ca86e6e9e4ab16bc4ca5dcddf818c195c5872cc9b68bde8d356d275bf1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.",
                "category": "company",
                "datetime": 1790592283,
                "headline": "FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals"
              },
              {
                "id": 142448557,
                "url": "https://finnhub.io/api/news?id=83fd6f88bbe0181d5e673078d88c7a25d5d42bea9269b446c04c471fc8a2ffdb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Xenon Pharmaceuticals (NASDAQ:XENE) said it has filed its first new drug application for azetukalner as a treatment for focal-onset seizures, while pausing portions of its late-stage psychiatry program to evaluate changes intended to improve tolerability. Speaking at the 2026 TD Cowen Neuropsychiat",
                "category": "company",
                "datetime": 1790524922,
                "headline": "Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review"
              },
              {
                "id": 142445831,
                "url": "https://finnhub.io/api/news?id=e9c507f01969153830318d3adb02f6e42f9540cb18b55eb73d8243e694c37524",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.",
                "category": "company",
                "datetime": 1790502600,
                "headline": "Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks."
              },
              {
                "id": 142437983,
                "url": "https://finnhub.io/api/news?id=f99f92cbdd159160feba9c7d4c9c3d12dcfbb7649a368adc49334c44589245cc",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/87466160/image_87466160.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Long-term bond yields persist, but investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks. Click for more.",
                "category": "company",
                "datetime": 1790417596,
                "headline": "Buy 5 Barron's Better Bets (Than T-Bills) Out Of 11 'Safer' September DiviDogs"
              },
              {
                "id": 142430488,
                "url": "https://finnhub.io/api/news?id=53ce5c17008a0d327ab70e12785f70737acdee150eb4e82609c3144bdb0db571",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid arthritis, and multiple sclerosis. It happened after three patients died from immune effector cell-associated hemophagocytic syndrome, a rare and severe immune reaction. […]",
                "category": "company",
                "datetime": 1790385904,
                "headline": "Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?"
              },
              {
                "id": 142432371,
                "url": "https://finnhub.io/api/news?id=403589f5a28b768b40e6b9e54ab5a5d2aa8836e772aecee6e6c1fa8830560d81",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Get the weekly summary of dividend changes for Dividend Champions, Contenders & Challengers, plus upcoming ex-dividend and pay dates.",
                "category": "company",
                "datetime": 1790377479,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week September 27"
              },
              {
                "id": 142424743,
                "url": "https://finnhub.io/api/news?id=fecd8a6719923821ab4cfc5440deb92c388d8b83d75441de3437cd5ff9cf75b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually received.",
                "category": "company",
                "datetime": 1790355822,
                "headline": "Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?"
              },
              {
                "id": 142423968,
                "url": "https://finnhub.io/api/news?id=95b29a5b2d13bf9364c61093b443793bb148ce86fccda508952a0896e100a9db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "PRINCETON, N.J., September 25, 2026--BMS Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial",
                "category": "company",
                "datetime": 1790344800,
                "headline": "Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma"
              },
              {
                "id": 142387643,
                "url": "https://finnhub.io/api/news?id=78c35e04c5723696eacf359b2c9b87d61cab10aed15b774d9a6d6db99d856175",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Key Stats for Acadia Pharmaceuticals StockToday’s Performance: -19%52-Week Range: $20 to $31Valuation Model Target Price: $34Implied Upside: 54%What Happened?Acadia Pharmaceuticals stock (NASDAQ: ACAD) is facing a major test over whether remlifanserin still has a credible path forward in Alzheimer’s disease psychosis after its Phase 2 trial narrowly missed its main goal. Remlifanserin is being developed to treat hallucinations and delusions associated with Alzheimer’s disease psychosis, an indic",
                "category": "company",
                "datetime": 1790289715,
                "headline": "Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026"
              },
              {
                "id": 142387642,
                "url": "https://finnhub.io/api/news?id=68daa9b6943eb4711d5e7e943cbb88a91f34379f88340feb66f1e2829d11d3f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol-Myers Squibb (NYSE:BMY) has picked Onco360 to join the restricted specialty pharmacy network for ZENBEXUS (iberdomide). ZENBEXUS, a newly approved therapy for certain multiple myeloma patients, will be dispensed through a Risk Evaluation and Mitigation Strategy program. Onco360 will handle specialty dispensing and clinical support for eligible patients as ZENBEXUS enters commercial rollout for an underserved group. The selection of Onco360 for ZENBEXUS distribution comes against...",
                "category": "company",
                "datetime": 1790288129,
                "headline": "Bristol Myers Squibb (BMY) Adds Restricted Pharmacy Path For New Myeloma Drug"
              },
              {
                "id": 142386723,
                "url": "https://finnhub.io/api/news?id=06486dec57fd728835475884e196e299d45e921f3c7692c30f8b299f17d29284",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Tesla, Bank of America and Coca-Cola headline today's research, with growth drivers, investment plans and key risks in focus.",
                "category": "company",
                "datetime": 1790279700,
                "headline": "Top Stock Reports for Tesla, Bank of America & Coca-Cola"
              },
              {
                "id": 142384798,
                "url": "https://finnhub.io/api/news?id=5c75fe4403d561735f911801b11e95fd082edf6b8b4b7324f9c26adfaa81fa19",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.",
                "category": "company",
                "datetime": 1790268120,
                "headline": "Why Women-Run Companies Deserve a Place in Your Portfolio"
              },
              {
                "id": 142384704,
                "url": "https://finnhub.io/api/news?id=0cedb1a9c0fb655179dee59641006bb11b965ee76575ca011c5995ecb7700cd3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibbs' growth portfolio is gaining ground, with newer drugs offsetting mature-product declines and reshaping its revenue mix.",
                "category": "company",
                "datetime": 1790266080,
                "headline": "Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY?"
              },
              {
                "id": 142374473,
                "url": "https://finnhub.io/api/news?id=37a2236581aa6f4e4380471327912ce854624a9338b83e5d4825f9e495819ff1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.",
                "category": "company",
                "datetime": 1790250961,
                "headline": "Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now?"
              },
              {
                "id": 142374474,
                "url": "https://finnhub.io/api/news?id=9d3cdee630a1a172739a9fff834976c4f76a026b684eb74eff4a9b18bd252387",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Helen McGuire and Camilo Manchola discuss advancing lung cancer care by leveraging Brazil's existing tuberculosis platforms, proving the power of integrated, human-centered systems to stretch resources and improve patient outcomes.By Devex PartnershipsOriginally published on DevexNORTHAMPTON, MA / ACCESS Newswire / September 24, 2026 / In Brazil, lung cancer is a leading cause of cancer mortality, with approximately 85% of cases diagnosed at an advanced stage.",
                "category": "company",
                "datetime": 1790249340,
                "headline": "Leveraging Brazil's Health Networks for Early Lung Cancer Detection"
              },
              {
                "id": 142379679,
                "url": "https://finnhub.io/api/news?id=47fb0c0d1ea5d7f938146cd3d2cba6f7f12e5e792a65b7020e835a670e3f34b7",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/103332926/image_103332926.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BMY",
                "summary": "Novo Nordisk A/S’s 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.",
                "category": "company",
                "datetime": 1790242799,
                "headline": "Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine"
              },
              {
                "id": 142373855,
                "url": "https://finnhub.io/api/news?id=0f37f78634cbb97c98642d9143ca3a8533bc27fb2eccaf0393e5038f4ba20004",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BMY, HRTG, RDVT, NMR and ECO have been added to the Zacks Rank #1 (Strong Buy) List on September 24th, 2026.",
                "category": "company",
                "datetime": 1790239800,
                "headline": "New Strong Buy Stocks for September 24th"
              },
              {
                "id": 142373351,
                "url": "https://finnhub.io/api/news?id=a65ae5d59b2f3e885dda9d36a23b31e67908ad34d15d80095c1dfa24bd54de2c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "ECO, NMR, BMY made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 24th, 2026.",
                "category": "company",
                "datetime": 1790232780,
                "headline": "Best Income Stocks to Buy for September 24th"
              },
              {
                "id": 142364239,
                "url": "https://finnhub.io/api/news?id=de13b6af78ef60c3cd3755c387247dfa19877801097b46c7cd14e0b496479239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "RUTHERFORD, Calif., September 23, 2026--On Saturday, September 19, 2026, leaders in science, philanthropy, and business, community members, and advocates gathered at the Staglin Family Vineyard in Napa Valley for the 32nd annual One Mind Music Festival, presented by Bank of America and Bristol Myers Squibb. The event welcomed more than 500 guests and raised over $3.6M to advance mental health research and discovery.",
                "category": "company",
                "datetime": 1790190660,
                "headline": "Over $3.6M Raised to Build a More Connected Future of Mental Health at 32nd One Mind Music Festival Featuring The Fray"
              },
              {
                "id": 142363145,
                "url": "https://finnhub.io/api/news?id=5161f374f3deb629630ae40445292e5990c242ecad419df57bade675dd405271",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.",
                "category": "company",
                "datetime": 1790183924,
                "headline": "What Is AbbVie No Longer Telling You?"
              },
              {
                "id": 142363146,
                "url": "https://finnhub.io/api/news?id=7c6066d745e16db0599e75e745e060580c3f345bfc520df1443e1cb10391555b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.",
                "category": "company",
                "datetime": 1790181437,
                "headline": "What Is The Best Case For Pfizer Stock?"
              },
              {
                "id": 142362095,
                "url": "https://finnhub.io/api/news?id=6dc633dc3d05ff04cfd2f5260158c2060de38e796581ecf6de15ffca979ee37e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "The Rare Access Action Project (RAAP) announced today that Bristol Myers Squibb (BMS) has joined RAAP as its newest member, expanding the coalition of patient and life sciences stakeholders working together to address access and coverage challenges affecting people living with rare diseases.",
                "category": "company",
                "datetime": 1790172060,
                "headline": "New Member Alert: RAAP WELCOMES BRISTOL MYERS SQUIBB! BMS Joins as Newest Member of RAAP"
              },
              {
                "id": 142358849,
                "url": "https://finnhub.io/api/news?id=61805feacc3ee6da25ef098b50d7d4d2f0118e17a8074c3a4f616b5d00ed8e68",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions. Find out which one has held its streak for 64 straight years and whether the 6% yielder is a trap or a genuine opportunity.",
                "category": "company",
                "datetime": 1790168501,
                "headline": "4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout"
              },
              {
                "id": 142339882,
                "url": "https://finnhub.io/api/news?id=a8962ecbd35b33c0d4877e88033484063f9ae6df0220fbb98d418d294f173f16",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "A $6.5B Eli Lilly biomanufacturing facility broke ground at Houston’s Generation Park, Texas’ largest pharmaceutical investment to date.",
                "category": "company",
                "datetime": 1790088464,
                "headline": "Eli Lilly Breaks Ground on $6.5B Generation Park Facility"
              },
              {
                "id": 142339888,
                "url": "https://finnhub.io/api/news?id=521f537e1ccd22d016f77968e273dfe4cdf5c5888d6da300c4de98eb6b88ce02",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.",
                "category": "company",
                "datetime": 1790085012,
                "headline": "Could You Have Seen Merck Stock's Pipeline Run Coming?"
              },
              {
                "id": 142337706,
                "url": "https://finnhub.io/api/news?id=93ee11e969216f043a97b637ce8eef0d26325f1151ce7be2c5e31a719763b7b4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "BERLIN, September 22, 2026--AISB Network launches AISB Bind to improve prediction of how molecules bind for virtual screening and lead optimization",
                "category": "company",
                "datetime": 1790078400,
                "headline": "AISB Network Launches AISB Bind to Improve Prediction of How Molecules Bind for Virtual Screening and Lead Optimization"
              },
              {
                "id": 142336898,
                "url": "https://finnhub.io/api/news?id=30ade6995bc892c80adbf84f3e46e2fe8e1993bd8512c4acd8de0529b51de6f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BMY",
                "summary": "NORTHAMPTON, MA / ACCESS Newswire / September 22, 2026 / Originally published on DevexLung cancer remains the leading cause of cancer death worldwide, yet in resource-limited settings, patients face severe barriers to early diagnosis-while TB is regularly identified and treated, signs and indications of lung cancer are often overlooked. Nestory Masalu, Head of Oncology for the Catholic University of Health and Allied Sciences/Bugando Medical Center, explains how his team is dismantling these dia",
                "category": "company",
                "datetime": 1790076540,
                "headline": "Transforming Lung Cancer Care & Early Detection in Tanzania"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 219,
            "discarded_article_count": 185
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 22.3,
        "grade": "良好",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.7,
          "macdPoints": 3.2,
          "vcpPayload": {
            "vcp_pass": true,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(14.5%→9.7%)；跌縮量(近10日3日)；靠近20日高位；升放量(近10日2日)；Ready=Y；Confirm=Y",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 13165660,
              "down_days": 6,
              "vcp_ready": true,
              "above_ma50": false,
              "avg_vol_10": 13588360,
              "avg_vol_20": 13404810,
              "avg_vol_30": 13165660,
              "range_pct_10": 0.09682539682539684,
              "range_pct_20": 0.12666666666666662,
              "range_pct_30": 0.1450793650793652,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.0321062521742168,
              "dist_to_20d_high": 0.01762045844378599,
              "down_shrink_days": 3,
              "breakout_level_20d": 64.13,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.6673960612691462
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.3,
            "details": {
              "atrPct": 3.2561904761904765,
              "turnoverUsdM": 955.418499,
              "liquidityPoints": 0.6,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.BMY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 58.8972,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 1,
              "rsi_score": 2,
              "macd_score": 2.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 6.5,
            "take_profit_price": 67.6122,
            "target_multiplier": 1.9,
            "technical_strength": 1.78,
            "take_profit_percent": 7.3
          },
          "positionPoints": 1.3,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.512380952380953,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 2.0514,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3.26
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "強勢區",
      "score": 10,
      "value": 89.37
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0181
    },
    "kdj": {
      "d": 61.66,
      "j": 105.48,
      "k": 76.27,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 45.08
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 30316973,
      "recentSlope": -1899232.7,
      "previousSlope": -5897060
    },
    "rsi": 55.38,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 56.3745,
      "position": "SAR喺價下",
      "distancePct": 10.52,
      "previousTrend": "上升"
    },
    "ma50": 63.2616,
    "macd": {
      "macd": -0.5886691437478007,
      "trend": "看漲",
      "signal": -1.1015017022141453,
      "histogram": 0.5128325584663447
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 8,
      "value": 60.4017,
      "position": "連續3日>VWAP",
      "consecutiveAbove": 3
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.13,
      "score": 6,
      "avgVolume": 13417984,
      "currentVolume": 15165373
    },
    "derived": {
      "ma20": 60.4945,
      "ma50": 63.2616,
      "prevClose": 61.12,
      "avgVolume10": 13797837,
      "avgVolume20": 13417984,
      "changePercent": 3.08,
      "avgVolumeForScore": 13417984
    },
    "ma_cross": {
      "ma20": 60.4945,
      "ma50": 63.2616,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 60.4195,
      "prevMa50": 63.2756,
      "spreadPct": 4.37,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 56.7353,
      "upper": 64.2537,
      "position": "上半部"
    },
    "rsi_short": 72.36,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.13
    }
  }
}

{
  "close": 63,
  "volume": 15165373,
  "changePercent": 3.08
}